Tetracyclic compounds for treating brain disorders

Abstract

Provided herein are tetracyclic heterocyclic compounds that may be useful in methods of treating disease or enhancing neuroplasticity. The compounds may also be useful for increasing dendritic spine density.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims exclusivity to U.S. Provisional Patent Application No. 63 / 174,266, filed April 13, 2021, which is hereby incorporated by reference in its entirety for all purposes.

[0002] STATEMENT REGARDING DIRECT RIGHTS TO ARTICLE MADE WITH U.S. GOVERNMENT RESEARCH OR DEVELOPMENT SUPPORT This invention was made with Government support under Grant No. R01GM128997 awarded by the National Institutes of Health. The Government has certain rights in this invention. [Background technology]

[0003] background Changes in synaptic connectivity and plasticity have been observed in the brains of individuals suffering from neuropsychiatric and neurological diseases / disorders. Psychoplastogens promote neuronal growth and improve neuronal structure through mechanisms that may involve activation of serotonin 5-HT2 receptors. Modulators of these biological targets, such as N,N-dimethyltryptamine (DMT), ibogaine, and lysergic acid diethylamide (LSD), have demonstrated psychoplastogenic properties. For example, LSD and other analogs of the ergoline scaffold can correct deleterious changes in neuronal structure associated with neuropsychiatric and neurological diseases / disorders. Such structural changes include, for example, loss of dendritic spines and synapses in the prefrontal cortex (PFC), as well as reduced complexity of dendritic arborization. Additionally, pyramidal neurons in the PFC exert top-down control over brain regions that control motivation, fear, reward, and cognition. Hallucinogenic psychoplastogens have demonstrated antidepressant, anxiolytic, and anti-addictive effects in clinical practice. However, their subjective effects limit their clinical usefulness. Moreover, hallucinogenic compounds are contraindicated for psychotic illnesses such as schizophrenia, which are well known to be associated with loss of dendritic spines in the PFC. Thus, non-hallucinogenic psychoplastogens may have clear advantages over their hallucinogenic counterparts.

[0004] Provided herein are compounds with improved physiochemical properties and clinically relevant therapeutic efficacy that have reduced hallucinogenic (e.g., non-hallucinogenic) properties compared to their hallucinogenic (e.g., ergoline) counterparts. Summary of the Invention

[0005] BRIEF SUMMARY OF THE PRESENTINVENTION In one embodiment, the compound of formula (K): [ka] {In the formula, Each R 1a , R 1b , R 1c , and R1d are independent of each other, H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, halogen, C 1-6 Haloalkyl, C 1-6 haloalkoxy, -NO2, or -CN; or two R on adjacent ring atoms. 1a The groups are combined to form C 4-8 forming a cycloalkyl or a 4-8 membered heterocycloalkyl having 1-2 heteroatoms each independently being N, O, or S; R 2a and R 2b are independently H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, C 1-6 Haloalkyl or C 1-6 haloalkoxy; or R 2a and R 2b combine to form a 4-8 membered heterocycloalkyl having 1-2 heteroatoms, each independently N, O, or S; R 3 , H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, C 1-6 Haloalkyl or C 1-6 haloalkoxy; R 3a is absent or C 1-6 alkyl; or R 3 and R 3a combine to form a 3-8 membered heterocycloalkyl having 1-2 heteroatoms, each independently N, O, or S; The subscripts m and p are each independently 0 to 2; and and the subscripts n and r are each independently 0 to 3}, or a pharma- ceutically acceptable salt thereof.

[0006] In another embodiment, the compound of formula (J): [ka] {In the formula, Each R 1a , R 1b , R 1c , and R 1d are independent of each other, H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, halogen, C 1-6 Haloalkyl, C 1-6 haloalkoxy, -NO2, or -CN; or two R on adjacent ring atoms. 1a The groups are combined to form C 4-8 forming a cycloalkyl or a 4-8 membered heterocycloalkyl having 1-2 heteroatoms each independently being N, O, or S; R 2a and R 2b are independently H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, C 1-6 Haloalkyl or C 1-6 haloalkoxy; or R 2a and R 2b combine to form a 4-8 membered heterocycloalkyl having 1-2 heteroatoms, each independently N, O, or S; R 3 , H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, C 1-6 Haloalkyl or C 1-6 haloalkoxy; The subscripts m and p are each independently 0 to 2; and and the subscripts n and r are each independently 0 to 3}, or a pharma- ceutically acceptable salt thereof.

[0007] In another embodiment, the present invention provides a compound having the following structure: [ka] The present invention provides a crystalline compound of (7aS,10R)-10-(diethylcarbamoyl)-8,8-dimethyl-7a,8,9,10-tetrahydro-7H-indolo[7,1-fg][1,7]naphthyridin-8-ium iodide having the formula:

[0008] In another embodiment, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention, or a pharma- ceutically acceptable salt thereof.

[0009] In another embodiment, provided herein is a method of treating a disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention, or a pharma- ceutically acceptable salt thereof, thereby treating the disease.

[0010] In another embodiment, provided herein is a method of enhancing neuroplasticity, comprising contacting a neuronal cell with a compound of the present invention, or a pharma- ceutical acceptable salt thereof, in an amount sufficient to enhance neuroplasticity of the neuronal cell, wherein the compound causes the maximum number of dendritic intersections to increase by more than 1.0-fold according to Sholl analysis.

[0011] In another embodiment, provided herein is a method of enhancing neuroplasticity and increasing dendritic spine density, comprising contacting a neuronal cell with a compound of the present invention, or a pharma- ceutical acceptable salt thereof, in an amount sufficient to enhance neuroplasticity and increase dendritic spine density of the neuronal cell. [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 shows the structural basis for the rational design of JRT, including a comparison of the structures of N,N-dimethyltryptamine and LSD with N,N-dimethyl-isotryptamine and JRT.

[0013] [Diagram 2] FIG. 2 shows that the total synthesis of (±)-JRT was completed in 12 steps and in 11% overall yield.

[0014] [Figure 3A-3E] 3A-E show that (+)-JRT is highly selective for serotonin receptors. FIG. 3A shows the binding profile of (+)-JRT and (-)-JRT compared to (+)-LSD. Orange and white cells show Ki values ​​below or above 10 μM, respectively. FIG. 3B shows that conventional GPCR binding and functional assays show that (+)-JRT is a potent agonist of the 5-HT2 receptor. FIG. 3C-E shows that PsychLight assays show that (+)-JRT and (-)-JRT have low hallucinogenic potential. FIG. 3C shows representative images of PSYLI2 cells after treatment in agonist mode. FIG. 3D shows a concentration-response psychLight assay performed in agonist mode. FIG. 3E shows a single concentration psychLight assay (1 μM) performed in antagonist mode.

[0015] [Figure 4] Figure 4 shows that (+)-JRT promotes structural plasticity in vivo. Using electron microscopy, we demonstrated that a single dose of (+)-JRT (1 mg / kg) increased dendritic spine density in the PFC 24 h after administration. Data represent spines counted in 5-8 dendritic segments per animal with 3 animals per group.

[0016] [Figure 5A-5D]Figures 5A-5D show that (+)-JRT exhibits antipsychotic, antidepressant, and cognition-enhancing effects in vivo. Figure 5A shows that mouse head twitch response (HTR) assays in male and female animals demonstrate that (+)-JRT has low hallucinogenic potential when the assays are performed in agonist mode. Furthermore, (+)-JRT (1 mg / kg) demonstrates antipsychotic properties by antagonizing HTR induced by LSD (0.2 mg / kg). Figure 5B shows that pretreatment with (+)-JRT (1 mg / kg) can block AMPH-induced hyperlocomotion in female but not male mice. Figure 5C shows that rat FST performed 24 hours after compound administration demonstrates that (+)-JRT produces antidepressant effects comparable to ketamine at substantially lower doses. Doses (mg / mL) are shown within or above the bars representing the various treatment groups. FIG. 5D shows that the 4-odor discrimination and reversal assay demonstrates that (+)-JRT does not affect stimulus discrimination but rescues cognitive impairment caused by unpredictable mild stress. AMPH=D-amphetamine.

[0017] [Figure 6] Figure 6 shows the selectivity profile of (+)-JRT and (-)-JRT across 55 central nervous system targets. The effects of (+)-JRT (10 μM) and (-)-JRT (10 μM) on various targets were evaluated by Eurofins Discovery. Assays were performed in duplicate and results were averaged. Targets with ≥ 50% inhibition are highlighted in blue.

[0018] [Figure 7] FIG. 7 shows the NMR of compounds 14 and 15 in thermodynamic equilibrium.

[0019] [Figure 8] FIG. 8 shows the chiral HPLC graph for (±)-JRT.

[0020] [Figure 9] FIG. 9 shows the chiral HPLC graph for (-)-JRT.

[0021] [Figure 10] FIG. 10 shows the chiral HPLC graph for (+)-JRT.

[0022] [Figure 11] Figure 11 shows the X-ray crystal structure for 16. One molecule of 16 and one solvent molecule of DCM are present. Atom numbering corresponds to the atomic coordinates provided. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0023] Detailed Description of the Invention I. General Tetracyclic ergoline analogs of heterocyclic compounds are provided herein.The compounds of the present invention are useful for treating diseases such as brain disorders, neuropsychiatric diseases, and other neurological diseases.The compounds of the present invention are also useful for enhancing neuroplasticity, increasing dendritic spine density, or both. II. Definition

[0024] Unless otherwise specifically indicated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition, any methods or materials similar or equivalent to those described herein may be used in the practice of the present invention. For purposes of the present invention, the following terms are defined:

[0025] "A," "an," or "the" not only include aspects with one component, but also aspects with multiple components. For example, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells, reference to "the agent" includes reference to one or more agents known to those of skill in the art, and so forth.

[0026] "Alkyl" refers to a straight or branched, saturated, aliphatic group having the indicated number of carbon atoms. The disclosure provided herein of "alkyl" is intended to encompass the independent description of saturated alkyl, unless otherwise specified. The alkyl groups described herein are generally monovalent, but may also be divalent, which may be described herein as "alkylene" or "alkylenyl" groups. Alkyl refers to any group having a C 1-2 , C 1-3 , C 1-4 , C 1-5 , C 1-6 , C 1-7 , C 1-8 , C 1-9 , C 1-10 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 3-4 , C 3-5 , C 3-6 , C 4-5 , C 4-6 and C 5-6 For example, C 1-6 Alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, etc. Alkyl can also refer to alkyl groups having up to 20 carbon atoms, including, but not limited to, heptyl, octyl, nonyl, decyl, etc. Alkyl groups can be substituted or unsubstituted.

[0027] "Alkenyl" means a straight or branched chain hydrocarbon having at least two carbon atoms and at least one double bond. Alkenyl includes C, C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 2-7 , C 2-8 , C 2-9 , C 2-10 , C3, C 3-4 , C 3-5 , C 3-6 , C4, C 4-5 , C 4-6 , C5, C 5-6 Alkenyl groups may contain any number of carbons, such as C, C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C30, C41, C50, C60, C71, C82, C93, C94, C95, C106, C117, C128, C138, C140, C150, C162, C174, C186, C198, C199, C201, C211, C222, C30, C41, C52, C60, C71, C82, C93, C104, C115, C126, C138, C148, C152, C162, C174, C186, C199, C215, C222, C30, C41, C52, C60, C71, C82, C93, C106, C117, C128, C138, C142, C152, C162, C174, C186, C199, C215, C199, C225, C230, C240, C250, C30, C41, C52, C60, C71, C82, C93, C104, C115, C126, C138, C142, C152, C162, C174, C186, C199, C215, C199, C225, C230, C240, C30, C41, C52

[0028] "Alkynyl" means either a straight chain or branched hydrocarbon having at least two carbon atoms and at least one triple bond. Alkynyl is any of the C, C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 2-7 , C 2-8 , C 2-9 , C 2-10 , C3, C 3-4 , C 3-5 , C 3-6 , C4, C 4-5 , C 4-6 , C5, C 5-6Alkynyl groups may contain any number of carbons, such as C, C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C30, C41, C52, C60, C71, C82, C93, C94, C95, C96, C97, C98, C99, C101, C112, C123, C134, C145, C146, C157, C158, C161, C172, C183, C194, C195, C196, C197, C198, C199, C201, C213, C224, C236, C246, C257, C261, C272, C282, C301, C310, C320, C330, C340, C350, C360, C370, C380, C390, C410, C420, C430, C440, C450, C460, C470, C480, C490, C510, C520, C530, C60, C71, C72, C83, C94, C95, C96, C97, C98, C101, C112, C123, C134, C145, C157, C161, C172, C183, C197, C198, C213, C199, C221, C235, C241, C257, C3

[0029] "Alkoxy" refers to an alkyl group having an oxygen atom connecting the alkyl group to the point of attachment: alkyl-O-. Like the alkyl group, the alkoxy group can have any suitable number of carbon atoms, such as C1-6. Alkoxy groups include, for example, methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, and the like. Alkoxy groups may be further substituted with a variety of substituents described herein. Alkoxy groups may be substituted or unsubstituted.

[0030] "Alkoxyalkyl" refers to a group having an alkyl component and an alkoxy component, where the alkyl component links the heterocycloalkyl component to the point of attachment. The alkyl component is as defined above, except that it is at least divalent, i.e., alkylene, in order to link ... 0-6 , C 1-2 , C 1-3 , C 1-4 , C 1-5 , C 1-6 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 3-4 , C 3-5 , C 3-6 , C 4-5 , C 4-6 and C 5-6The alkyl group may contain any number of carbons, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63

[0031] "Halogen" refers to fluorine, chlorine, bromine, and iodine.

[0032] "Haloalkyl" refers to an alkyl as defined above, in which some or all of the hydrogen atoms are replaced with halogen atoms. As with alkyl groups, haloalkyl groups can have any suitable number of carbon atoms, such as C1-6. For example, haloalkyl includes trifluoromethyl, fluoromethyl, and the like. In some cases, the term "perfluoro" can be used to define a compound or radical in which all hydrogens are replaced with fluorine. For example, perfluoromethyl refers to 1,1,1-trifluoromethyl.

[0033] "Haloalkoxy" refers to an alkoxy group in which some or all of the hydrogen atoms are replaced with halogen atoms. Similar to alkyl groups, haloalkoxy groups can be C 1-6 Alkoxy groups can have any suitable number of carbon atoms, such as 1, 2, 3, or more. Alkoxy groups can be substituted with one, two, three, or more halogens. When all hydrogens are replaced with halogens, such as fluorine, the compound is fully substituted, such as perfluorinated. Haloalkoxy includes, but is not limited to, trifluoromethoxy, 2,2,2,-trifluoroethoxy, perfluoroethoxy, and the like.

[0034] "Cycloalkyl" means a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing 3 to 12 ring atoms, or the indicated number of atoms. Cycloalkyl is defined as any of the following: 3-6 , C 4-6 , C 5-6 , C 3-8 , C 4-8 , C 5-8 , C6-8 , C 3-9 , C 3-10 , C 3-11 , and C 3-12 In some embodiments, the cycloalkyl is a spiro ring or a bridged compound. In some embodiments, the cycloalkyl is optionally fused to an aromatic ring and the point of attachment is at a carbon that is not an aromatic ring carbon atom. Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Saturated bicyclic and polycyclic cycloalkyl rings include, for example, norbornane, [2.2.2]bicyclooctane, decahydronaphthalene, and adamantane. Cycloalkyl groups can also be partially unsaturated, with one or more double or triple bonds in the ring. Representative cycloalkyl groups that are partially unsaturated include, but are not limited to, cyclobutene, cyclopentene, cyclohexene, cyclohexadiene (1,3- and 1,4-isomers), cycloheptene, cycloheptadiene, cyclooctene, cyclooctadiene (1,3-, 1,4- and 1,5-isomers), norbornene, and norbornadiene. When cycloalkyl is a saturated monocyclic C3-8 cycloalkyl, exemplary groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. When cycloalkyl is a saturated monocyclic C 3-6 When it is cycloalkyl, exemplary groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Cycloalkyl groups can be substituted or unsubstituted.

[0035] "Heterocycloalkyl" refers to a cycloalkyl, as defined above, having 3-12 ring members and 1-4 N, O, and S heteroatoms. The heteroatoms may be oxidized, such as, but not limited to, -S(O)- and -S(O)2-. Heterocycloalkyl groups can contain any number of ring atoms, such as 3-6, 4-6, 5-6, 3-8, 4-8, 5-8, 6-8, 3-9, 3-10, 3-11, or 3-12 ring members. Any suitable number of heteroatoms can be included in a heterocycloalkyl group, such as 1, 2, 3, or 4, or 1-2, 1-3, 1-4, 2-3, 2-4, or 3-4. In some embodiments, a heterocycloalkyl is a spiro ring or bridged compound. In some embodiments, a heterocycloalkyl is optionally fused to an aromatic ring and the point of attachment is at a carbon or heteroatom (e.g., a nitrogen atom) that is not an aromatic ring carbon atom. Heterocycloalkyl groups may include groups such as aziridine, azetidine, pyrrolidine, piperidine, azepane, azocane, quinuclidine, pyrazolidine, imidazolidine, piperazine (1,2-, 1,3- and 1,4-isomers), oxirane, oxetane, tetrahydrofuran, oxane (tetrahydropyran), oxepane, thiirane, thietane, thiolane (tetrahydrothiophene), thiane (tetrahydrothiopyran), oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, dioxolane, dithiolane, morpholine, thiomorpholine, dioxane, or dithiane. Heterocycloalkyl groups may be fused to aromatic or non-aromatic ring systems to form members, including, but not limited to, indoline. Heterocycloalkyl groups may be unsubstituted or substituted. For example, heterocycloalkyl groups may be C 1-6 It may be substituted with alkyl or oxo (=O) or the like.

[0036] The heterocycloalkyl group can be attached through any position on the ring. For example, aziridine can be 1- or 2-azetidine, azetidine can be 1- or 2-azetidine, pyrrolidine can be 1-, 2-, or 3-pyrrolidine, piperidine can be 1-, 2-, 3-, or 4-piperidine, pyrazolidine can be 1-, 2-, 3-, or 4-pyrazolidine, imidazolidine can be 1-, 2-, 3-, or 4-imidazolidine, and piperazine can be 1-, 2-, 3-, or 4-piperazine. where tetrahydrofuran can be 1- or 2-tetrahydrofuran, oxazolidine can be 2-, 3-, 4-, or 5-oxazolidine, isoxazolidine can be 2-, 3-, 4-, or 5-isoxazolidine, thiazolidine can be 2-, 3-, 4-, or 5-thiazolidine, isothiazolidine can be 2-, 3-, 4-, or 5-isothiazolidine, and morpholine can be 2-, 3-, or 4-morpholine.

[0037] When a heterocycloalkyl contains 3-8 ring members and 1-3 heteroatoms, representative ring members include, but are not limited to, pyrrolidine, piperidine, tetrahydrofuran, oxane, tetrahydrothiophene, thiane, pyrazolidine, imidazolidine, piperazine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, morpholine, thiomorpholine, dioxane, and dithiane. Heterocycloalkyls can also form rings with 5-6 ring members and 1-2 heteroatoms, representative ring members include, but are not limited to, pyrrolidine, piperidine, tetrahydrofuran, tetrahydrothiophene, pyrazolidine, imidazolidine, piperazine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, and morpholine.

[0038] The term "heterocycle" or "heterocyclic" refers to aromatic heterocycles (also known as heteroaryls) and heterocycloalkyl rings (also known as heteroalicyclic groups) containing 1-4 heteroatoms in the ring, where each heteroatom in the ring is selected from O, S, and N, and each heterocyclic group in the ring has 3-10 atoms in its ring system, with the proviso that no ring contains two adjacent O or S atoms. Unless otherwise specified in this specification, a heterocyclyl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which optionally includes fused or bridged ring systems. The heteroatoms in a heterocyclyl radical are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocyclyl radical is partially or fully saturated. The heterocyclyl is attached to the remainder of the molecule by any atom of the ring. Non-aromatic heterocyclic groups (also known as heterocycloalkyls) include rings having 3 to 10 atoms in their ring system, and aromatic heterocyclic groups include rings having 5 to 10 atoms in their ring system. Heterocyclic groups include benzo-fused ring systems.Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, pyrrolin-2-yl, pyrrolin-3-yl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiamine ... oranyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl, indolin-2-onyl, isoindolin-1-onyl, isoindolin-1,3-dionyl, 3,4-dihydroisoquinolin-1(2H)-onyl, 3,4-dihydroquinolin-2(1H)-onyl, isoindolin-1,3-dithionyl, benzo[d]oxazol-2(3H)-onyl, 1H-benzo[d]imidazol-2(3H)-onyl, benzo[d]thiazol-2(3H)-onyl, and quinolizinyl. Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. The foregoing groups may be C-linked (or C-linked) or N-linked where possible. For example, groups derived from pyrrole include pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).Further, groups derived from imidazole include imidazol-1-yl or imidazol-3-yl (both N-linked), or imidazol-2-yl, imidazol-4-yl, or imidazol-5-yl (all C-linked). Heterocyclic groups include benzo-fused ring systems. Non-aromatic heterocycles are optionally substituted with one or two oxo (=O) moieties, such as pyrrolidin-2-one. In some embodiments, at least one of the two rings of a bicyclic heterocycle is aromatic. In some embodiments, both rings of a bicyclic heterocycle are aromatic. Unless otherwise stated in this specification, the term "heterocyclyl" is meant to include heterocyclyl radicals as defined above optionally substituted by one or more substituents selected from the following: alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R. y -OR x , -R y -OC(O)-R x , -R y -OC(O)-OR x , -R y -OC(O)-N(R x )2, -R y -N(R x )2, -R y -C(O)R x , -R y -C(O)OR x , -R y -C(O)N(R x )2, -R y -O-Rz-C(O)N(R x )2, -R y -N(R x )C(O)OR x , -R y -N(Rx )C(O)R x , -R y -N(R x )S(O) t R x (t is 1 or 2), -R y -S(O) t R x (t is 1 or 2), -R y -S(O) t OR x (t is 1 or 2), and -R y -S(O) t N(R x )2 (t is 1 or 2) (where R x are each independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl); R y are each independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rz is a straight or branched alkylene or alkenylene chain, wherein each of the above substituents is unsubstituted unless otherwise specified.

[0039] "Salt" refers to an acid salt or base salt of the compound used in the method of the present invention. Illustrative examples of pharmaceutically acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, etc.) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid, etc.) salts, and quaternary ammonium (methyl iodide, ethyl iodide, etc.) salts. It is understood that pharmaceutically acceptable salts are non-toxic. Further information regarding suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference.

[0040] Pharmaceutically acceptable salts of acidic compounds of the invention are salts formed with bases, i.e. cationic salts such as alkali metal salts and alkaline earth metal salts, e.g., sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, and ammonium salts, e.g., ammonium salts, trimethyl-ammonium salts, diethylammonium salts, and tris-(hydroxymethyl)-methyl-ammonium salts.

[0041] Similarly, acid addition salts of mineral acids, organic carboxylic acids and organic sulfonic acids, such as hydrochloric acid, methanesulfonic acid, maleic acid and the like, are possible provided that a basic group, such as pyridyl, forms part of the structure.

[0042] The neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for purposes of the invention.

[0043] A "therapeutically effective amount or dose", "therapeutically sufficient amount or dose" or "effective or sufficient amount or dose" refers to a dose that produces the therapeutic effect for which it is administered. The exact dose depends on the purpose of the treatment and can be ascertained by one of skill in the art using known techniques (see, for example, Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins). In sensitized cells, the therapeutically effective amount is often less than the conventional therapeutically effective amount in non-sensitized cells.

[0044] "Treat", "treating", and "treatment" refer to any indication of success in treating or ameliorating an injury, pathology, condition, or symptom (e.g., pain), including objective or subjective parameters, such as remission, remission, relief of symptoms, or making the symptom, injury, pathology, or condition more tolerable to the patient, reducing the frequency or persistence of the symptom or condition, or, in some circumstances, preventing the onset of the symptom. Treatment or amelioration of a symptom can also be based on any objective or subjective parameter, including, for example, the results of a physical examination.

[0045] "Disease" refers to abnormal cellular function within an organism and is not the direct result of physical or external injury. Disease can refer to any condition that causes distress, dysfunction, incapacity, disability, infection, pain, or even death. Diseases include, but are not limited to, genetic diseases, such as genetic and non-genetic diseases, infectious diseases, non-infectious diseases, such as cancer, deficiency diseases, neurological diseases, and physiological diseases.

[0046] "Administering" refers to oral administration, administration as a suppository, topical contact, parenteral, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, intrathecal administration, or implantation of a sustained release device, e.g., a mini-osmotic pump, to a subject.

[0047] "Subject" refers to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, etc. In certain embodiments, the subject is a human.

[0048] "Neuroplasticity" refers to the ability of the brain to continually change its structure and / or function throughout a subject's life. Examples of changes to the brain include, but are not limited to, the ability to adapt or respond to internal and / or external stimuli, such as injury, and the ability to generate new neurites, dendritic spines, and synapses.

[0049] "Dendrite intersections" refer to dendritic branches that overlap or cluster with each other. Dendritic intersections are measured by Sholl analysis.

[0050] "Dendrite spine" refers to a small membrane protruding from a dendrite that can receive electrical signals from the axon at a synapse. Dendritic spines are useful for transmitting electrical signals to the neuron's cell body. A single neuron's dendrite may contain hundreds to thousands of spines. Dendritic spine density refers to the number of spines within the length of a dendrite. -1 A dendritic spine density of 5 spines per 1 μm of dendrite.

[0051] "Modulate" or "modulating" or "modulation" refers to an increase or decrease in the amount, quality, or effect of a particular activity, function, or molecule. By way of example and not by way of limitation, G protein-coupled receptors (e.g., 5HT 2A or 5HT 2C) agonists, partial agonists, antagonists, and allosteric modulators (eg, positive allosteric modulators) are modulators of the receptor.

[0052] "Agonism" refers to the activation of a receptor or enzyme by a modulator or agonist, resulting in a biological response.

[0053] "Agonist" refers to a modulator that binds to a receptor or enzyme and activates the receptor to produce a biological response. By way of example only, "5HT 2A The "agonist" is a 5HT antagonist with a potency of approximately 100 μM or less. 2A Regarding activity EC 50 In some embodiments, the term "agonist" includes full agonists or partial agonists. A "full agonist" refers to a modulator that binds to and activates a receptor with the maximal response that an agonist produces at the receptor. A "partial agonist" refers to a modulator that binds to and activates a given receptor but has partial efficacy, i.e., a less than maximal response at the receptor relative to a full agonist. A "functionally selective agonist" refers to a modulator that produces one or a subset of the biological responses possible through activation of the receptor. For example, 5HT 2A Activation of the 5HT receptor is known to induce many downstream effects, including enhanced neuroplasticity, increased intracellular calcium concentration, and hallucinations, among many other biological responses. 2A Activation of the receptor will produce only a portion of the possible biological responses.

[0054] A "positive allosteric modulator" refers to a modulator that binds to a site other than the orthosteric binding site and enhances or amplifies the effect of an agonist.

[0055] "Antagonism" refers to the inactivation of a receptor or enzyme by a modulator or antagonist. Receptor antagonism, for example, is when a molecule is unable to bind to a receptor and cause activity. A "functionally selective antagonist" blocks some signaling pathways while leaving others unaffected.

[0056] "Antagonist" or "neutral antagonist" refers to a modulator that binds to a receptor or enzyme and prevents a biological response. Antagonists have no activity in the absence of an agonist or inverse agonist, but can prevent the activity of either, resulting in no change in the biological response. III. Compound

[0057] The present invention provides tetracyclic heterocyclic compounds useful for treating a variety of neurological diseases and disorders, as well as for enhancing neuroplasticity.

[0058] In some embodiments, the compounds provided herein have improved physiochemical properties as a result of the loss of hydrogen bond donors, reduced total polar surface area, and improved central nervous system multiparameter optimization (MPO) scores. Hallucinogenic 5-HT modulators (e.g., 5HT 2A and / or 5HT 2C In some embodiments, non-hallucinogenic compounds described herein have been shown to be effective in treating neurological disorders, such as hallucinogenic 5-HT modulators (e.g., 5HT 2A and / or 5HT 2C Modulators) provide better therapeutic efficacy.

[0059] Provided herein are heterocyclic compounds useful for treating various diseases, such as brain disorders and other conditions.In some embodiments, provided herein are heterocyclic compounds that are 5-HT2 modulators and promote neuroplasticity (e.g., cortical structural plasticity).

[0060] In some embodiments, the compound of formula (K): [ka] {In the formula, Each R 1a , R 1b , R 1c , and R 1d are independent of each other, H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, halogen, C 1-6 Haloalkyl, C 1-6 haloalkoxy, -NO2, or -CN; or two R on adjacent ring atoms. 1a The groups are combined to form C 4-8 forming a cycloalkyl or a 4-8 membered heterocycloalkyl having 1-2 heteroatoms each independently being N, O, or S; R 2a and R 2b are independently H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, C 1-6 Haloalkyl or C 1-6 haloalkoxy; or R 2a and R 2b combine to form a 4-8 membered heterocycloalkyl having 1-2 heteroatoms, each independently N, O, or S; R 3 , H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, C 1-6 Haloalkyl or C 1-6 haloalkoxy; R 3a is absent or C 1-6 alkyl; or R 3 and R 3acombine to form a 3-8 membered heterocycloalkyl having 1-2 heteroatoms, each independently N, O, or S; The subscripts m and p are each independently 0 to 2; and and the subscripts n and r are each independently 0 to 3}, or a pharma- ceutically acceptable salt thereof.

[0061] In some embodiments, the compound of formula (J): [ka] {In the formula, Each R 1a , R 1b , R 1c , and R 1d are independent of each other, H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, halogen, C 1-6 Haloalkyl, C 1-6 haloalkoxy, -NO2, or -CN; or two R on adjacent ring atoms. 1a The groups are combined to form C 4-8 forming a cycloalkyl or a 4-8 membered heterocycloalkyl having 1-2 heteroatoms each independently being N, O, or S; R 2a and R 2b are independently H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, C 1-6 Haloalkyl or C 1-6 haloalkoxy; or R 2a and R 2b combine to form a 4-8 membered heterocycloalkyl having 1-2 heteroatoms, each independently N, O, or S; R 3 , H, C 1-6Alkyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, C 1-6 Haloalkyl or C 1-6 haloalkoxy; The subscripts m and p are each independently 0 to 2; and and the subscripts n and r are each independently 0 to 3}, or a pharma- ceutically acceptable salt thereof.

[0062] In some embodiments, the compound of formula (I): [ka] Provided herein are compounds having the structure: or a pharma- ceutically acceptable salt thereof.

[0063] In some embodiments, the compound of formula (Ia), (Ib), (Ic), or (Id) is represented by the following formula: [ka] Provided herein are compounds having the structure: or a pharma- ceutically acceptable salt thereof.

[0064] In some embodiments, the compound of formula (Ia): [ka] Provided herein are compounds having the structure:

[0065] In some embodiments, the compound of formula (Ib): [ka] Provided herein are compounds having the structure:

[0066] In some embodiments, the compound of formula (Ic): [ka] Provided herein are compounds having the structure:

[0067] In some embodiments, the compound of formula (Id): [ka] Provided herein are compounds having the structure:

[0068] R 1a may be any suitable functional group. In some embodiments, R 1a , H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, halogen, C 1-6 Haloalkyl, C 1-6 haloalkoxy, -NO, or -CN. In some embodiments, R 1a , H, C 1-6 Alkyl, C 1-6 In some embodiments, R 1a , H, C 1-6 In some embodiments, R 1a is H.

[0069] R 2a and R 2b can be any suitable functional group. In some embodiments, R 2a and R 2b are independently H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, C 1-6 Haloalkyl or C 1-6 haloalkoxy; or R 2a and R 2bare combined to form a 4-8 membered heterocycloalkyl having 1-2 heteroatoms, each independently being N, O, or S. In some embodiments, R 2a and R 2b are independently H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxyalkyl, or C 1-6 In some embodiments, R 2a and R 2b are each independently H or C 1-6 In some embodiments, R 2a and R 2b are each independently 1-6 In some embodiments, R 2a and R 2b are each independently ethyl.

[0070] R 3 can be any suitable functional group. In some embodiments, R 3 , H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, C 1-6 Haloalkyl or C 1-6 In some embodiments, R 3 is H or C 1-6 In some embodiments, R 3 is C 1-6 In some embodiments, R 3 is methyl.

[0071] In some embodiments, R 3a is either absent or C 1-6 In some embodiments, R 3a is absent. In some embodiments, R 3a is C 1-6 In some embodiments, R 3ais methyl.

[0072] The subscripts m, n, p, and r can be any suitable integer. In some embodiments, the subscripts m and p are each independently 0 to 2; and the subscripts n and r are each independently 0 to 3. In some embodiments, n is 0.

[0073] In some embodiments, the structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0074] In some embodiments, the structure: [ka] Provided herein are compounds having the formula:

[0075] In some embodiments, the structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0076] In some embodiments, the structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0077] In some embodiments, the structure: [ka] Provided herein are compounds having the formula:

[0078] In some embodiments, the structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0079] In some embodiments, the structure: [ka] Provided herein are compounds having the formula:

[0080] In some embodiments, the structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0081] In some embodiments, the structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0082] In some embodiments, the structure: [ka] Provided herein are compounds having the formula:

[0083] In some embodiments, the present invention provides a compound having the following structure: [ka] The present invention provides a crystalline compound of (7aS,10R)-10-(diethylcarbamoyl)-8,8-dimethyl-7a,8,9,10-tetrahydro-7H-indolo[7,1-fg][1,7]naphthyridin-8-ium iodide having the formula:

[0084] The compounds of the present invention may also be in the form of salts, such as the acid salts or base salts of the compounds of the present invention. Illustrative examples of pharmaceutically acceptable salts are salts of mineral acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, etc.), salts of organic acids (such as fumaric acid, acetic acid, propionic acid, glutamic acid, citric acid, etc.), and salts of quaternary ammonium (such as methyl iodide, ethyl iodide, etc.). It is understood that pharmaceutically acceptable salts are non-toxic. Further information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference.

[0085] The present invention also includes isotopically labeled compounds of the invention, in which one or more atoms are replaced by one or more atoms having a specified atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, sulfur, and chlorine (e.g., 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 17 O. 18 F, 35 S and 36 Isotopically labeled compounds of the present invention are useful in tissue distribution assays of the compounds, and their prodrugs and metabolites; preferred isotopes for such assays include 3 H and 14 C. In addition, in certain circumstances, heavier isotopes such as deuterium ( 2Replacement with an isotopically labeled amine such as 1H may provide increased metabolic stability, which may result in therapeutic advantages such as increased half-life in vivo or reduced dose requirements. In general, isotopically labeled compounds of the present invention may be prepared according to methods known to those skilled in the art by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. Compounds of the present invention may be isotopically labeled at basic amines of aromatic rings and at positions adjacent to the methyl group of methoxy substituents.

[0086] The present invention includes all tautomers and stereoisomers of the compounds of the present invention, in mixtures or in pure or substantially pure form. The compounds of the present invention have asymmetric centers at carbon atoms, and therefore the compounds of the present invention may exist as diastereomers, enantiomers or mixtures thereof. All conformational isomers (e.g., cis and trans isomers) and all optical isomers (e.g., enantiomers and diastereomers), racemates, diastereomers and other mixtures of such isomers, as well as solvates, hydrates, isomorphs, polymorphs and tautomers, are within the scope of the present invention. The compounds according to the present invention may be prepared using diastereomers, enantiomers or racemic mixtures as starting materials. Furthermore, diastereomeric and enantiomeric products may be separated by chromatography, fractional crystallization or other methods known to those skilled in the art. 5-HT

[0087] 5-HT2 agonism correlates with the promotion of neuroplasticity (Ly et al., 2018). 5-HT2 antagonists abolish the neuritogenic and spinogenic effects of hallucinogenic compounds with 5-HT2 agonist activity, e.g., DMT, LSD, and DOI. Furthermore, DMT and other psychedelic compounds promote increased dendritic branching complexity, dendritic spine density, and synaptogenesis through 5-HT2-dependent processes. Importantly, the psychoplastogenic effects of the compounds provided herein were also blocked under these conditions, implicating 5-HT2 receptors in their mechanism of action. In addition, modulation of 5-HT2 receptors appears to be important in neuroplasticity and various psychological conditions, such as anxiety, depression, post-traumatic stress disorder (PTSD), and schizophrenia.

[0088] In addition, non-hallucinogenic compounds (e.g., lisuride and 6-MeO-DMT) have been shown to inhibit 5HT 2A When the sensor assay is performed in antagonist mode, it competes off 5-HT. In addition, compounds that are non-hallucinogenic in animals (e.g., humans), such as 6-F-DET, ketanserin, etc., compete off 5-HT in antagonist mode sensor assays. 2A In some embodiments, the compounds provided herein compete with the binding of 5HT to 5-HT. 2A In some embodiments, the 5HT 2A The sensor assay is in antagonist mode. In some embodiments, the compounds provided herein inhibit the 5HT 2A In some embodiments, the compounds provided herein inhibit the binding of 5-HT to 5HT 2A In some embodiments, the compounds provided herein inhibit the binding of 5-HT to 5HT in an antagonistic manner and are non-hallucinogenic. 2AIn some embodiments, the compounds provided herein are non-hallucinogenic, preventing the binding of 5-HT in antagonistic mode. In some embodiments, the compounds provided herein are non-hallucinogenic, preventing the binding of 5-HT in antagonistic mode. In some embodiments, the compounds provided herein are non-hallucinogenic, inhibiting the response of a sensor assay in antagonistic mode. In some embodiments, the compounds provided herein are non-hallucinogenic, inhibiting the response of a sensor assay in antagonistic mode.

[0089] In some embodiments, the effect of the compounds provided herein on the agonist mode of the sensor assay is determined by the compound inhibiting 5-HT 2A Receptors and / or 5-HT 2C In some embodiments, the effect of the compounds provided herein on the antagonist mode of the sensor assay indicates that the compounds are non-psychedelic ligands of the 5-HT 2A Receptors and / or 5-HT 2C In some embodiments, the effects of the compounds provided herein on both the agonist and antagonist modes of the sensor assays indicate that the compounds are non-psychedelic ligands of the 5-HT 2A Receptors and / or 5-HT 2C This suggests that it is a non-hallucinogenic ligand for the receptor.

[0090] In some embodiments, non-hallucinogenic compounds are described herein that exhibit similar therapeutic potential as hallucinogenic 5-HT2 agonists. In some embodiments, the non-hallucinogenic compounds described herein offer superior therapeutic potential for neurological disorders than hallucinogenic 5-HT2 agonists. In some embodiments, the compounds of the present invention are 5-HT 2A Receptors and / or 5-HT 2C It is a receptor modulator and promotes neuroplasticity (e.g., plasticity of cortical structures).

[0091] In some embodiments, the compounds provided herein are 5-HT 2A Receptors and / or 5-HT 2C In some embodiments, the compounds provided herein have activity at the 5-HT 2A Receptors and / or 5-HT 2C Elicit a biological response by activating receptors (e.g., allosteric modulation or 5-HT 2A Receptors and / or 5-HT 2C In some embodiments, the compounds provided herein selectively activate 5-HT 2A In some embodiments, the compounds provided herein are selective 5-HT 2C It is a modulator and promotes neuroplasticity (e.g., plasticity of cortical structures). In some embodiments, promoting neuroplasticity includes, for example, increasing dendritic spine growth, increasing the synthesis of synaptic proteins, strengthening synaptic responses, enhancing dendritic branching complexity, increasing dendritic branching content, increasing spine formation, increasing neurite formation, or any combination thereof. In some embodiments, enhancing neuroplasticity includes, for example, enhancing the plasticity of cortical structures in the anterior part of the brain.

[0092] In some embodiments, the compounds provided herein (e.g., 5-HT 2A Modulators and / or 5-HT 2C In some embodiments, the compounds provided herein (e.g., 5-HT modulators) are non-hallucinogenic. 2A Modulators and / or 5-HT 2CModulators) are used to treat neurological disorders, and the modulators do not induce dissociative side effects. In some embodiments, the hallucinogenic potential of the compounds described herein is evaluated in vitro. In some embodiments, the hallucinogenic potential of the compounds described herein evaluated in vitro is compared to the hallucinogenic potential of a hallucinogenic homolog evaluated in vitro. In some embodiments, the compounds provided herein do not elicit as much non-hallucinogenic potential in vitro as the hallucinogenic homolog.

[0093] In some embodiments, the compounds provided herein (e.g., 5-HT 2A Modulators and / or 5-HT 2C In some embodiments, the neurological disease is characterized by a decrease in neuroplasticity, a decrease in plasticity of cortical structures, a decrease in 5-HT 2A Decreased receptor content, 5-HT 2C These include increased receptor content, decreased dendritic branching complexity, loss of dendritic spines, decreased dendritic branch content, decreased spine formation, decreased neurite formation, neurite retraction, or any combination thereof.

[0094] In some embodiments, the compounds provided herein (e.g., 5-HT 2A Modulators and / or 5-HT 2C In some embodiments, the compounds provided herein (e.g., 5-HT modulators) are used to increase neuroplasticity. 2A Modulators and / or 5-HT 2C In some embodiments, the compounds provided herein (e.g., 5-HT modulators) are used to treat brain disorders. 2A Modulators and / or 5-HT 2C The modulators are used to increase at least one of the translation, transcription, or secretion of a neurotrophic factor.

[0095] In some embodiments, the compounds provided herein, including pharma- ceutically acceptable salts and solvates thereof, are non-hallucinogenic psychoplastogens that promote neuronal growth, improve neuronal structure, or a combination thereof. IV. Pharmaceutical Compositions and Formulations

[0096] In some embodiments, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention, or a pharma- ceutically acceptable salt thereof.

[0097] The compositions of the present invention may be prepared in a wide variety of oral, parenteral and topical dosage forms. Oral preparations include tablets, pills, powders, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, and the like, suitable for oral ingestion by the patient. The compositions of the present invention may also be administered by injection, i.e., intravenously, intramuscularly, intradermally, subcutaneously, intraduodenally, or intraperitoneally. The compositions described herein may also be administered by inhalation, for example, intranasally. Additionally, the compositions of the present invention may be administered transdermally. The compositions of the present invention may also be administered by intraocular, intravaginal and intrarectal routes (including suppositories), insufflation, powders, and aerosol formulations (for examples of steroid inhalants, see Rohatagi, J. Clin. Pharmacol. 35:1187-1193, 1995; Tjwa, Ann. Allergy Asthma Immunol. 75:107-111, 1995). Thus, the present invention also provides a pharmaceutical composition comprising a pharma- ceutically acceptable carrier or excipient and a compound of the present invention.

[0098] For preparing pharmaceutical compositions from the compounds of the present invention, pharma- ceutical acceptable carriers can be solid or liquid.Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories and dispersible granules.Solid carriers can be one or more substances that can act as diluents, flavorings, binders, preservatives, tablet disintegrating agents or encapsulating materials.Details regarding procedures for formulation and administration are fully described in the scientific and patent literature, see, for example, the latest edition of Remington's Pharmaceutical Sciences, Maack Publishing Co, Easton PA ("Remington's").

[0099] In powders, the carrier is a finely divided solid that is in a mixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compressed into the desired shape and size. The powders and tablets preferably contain 5% or 10% to 70% of the compound of the present invention.

[0100] Suitable solid excipients include, but are not limited to, magnesium carbonate, magnesium stearate, talc, pectin, dextrin, starch, tragacanth, low melting waxes, cocoa butter, carbohydrates, sugars (including but not limited to lactose, sucrose, mannitol or sorbitol, starches derived from corn, wheat, rice, potato or other plants), celluloses (e.g., methylcellulose, hydroxypropylmethyl-cellulose or sodium carboxymethylcellulose), and gums (including acacia and tragacanth), and proteins (including but not limited to gelatin and collagen). If desired, disintegrating or solubilizing agents may be added (e.g., cross-linked polyvinylpyrrolidone, agar, alginic acid or a salt thereof (e.g., sodium alginate)).

[0101] Dragee cores are provided with suitable coatings such as gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and / or titanium dioxide, lacquer solutions, and concentrated sugar solutions which may also contain suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to identify the amount of active compound (i.e., dosage). The pharmaceutical preparations of the present invention may also be used orally using, for example, push-fit capsules made of gelatin, as well as soft sealed capsules made of gelatin and a coating such as glycerol or sorbitol. Push-fit capsules may contain the compound of the present invention mixed with fillers or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, if necessary, stabilizers. In soft capsules, the compound of the present invention may be dissolved or suspended in suitable liquids such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

[0102] For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the compound of the present invention is dispersed homogeneously therein by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.

[0103] Liquid form preparations include solutions, suspensions and emulsions, for example, water or water / propylene glycol solutions.For parenteral injection, liquid preparations can be formulated in solutions in aqueous polyethylene glycol solution.

[0104] Aqueous solutions suitable for oral use can be prepared by dissolving the compounds of the invention in water and adding suitable colorants, flavorings, stabilizers and thickening agents, as desired. Aqueous suspensions suitable for oral use are prepared by mixing the finely divided active ingredient with a viscous material (e.g., natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum arabic) and a dispersing or wetting agent (e.g., naturally occurring phosphatides (e.g., lecithin), condensation products of alkylene oxides with fatty acids (e.g., polyoxyethylene stearate), condensation products of ethylene oxide with long chain aliphatic alcohols (e.g., heptadecaethyleneoxycetanol), condensation products of ethylene oxide with fatty acids and heptadecaethyleneoxycetanol). The aqueous suspension may be prepared by dispersing in water with a condensation product of ethylene oxide with a partial ester derived from a xylitol (e.g., polyoxyethylene sorbitol mono-oleate) or a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan mono-oleate). The aqueous suspension may also contain one or more preservatives (e.g., ethyl p-hydroxybenzoate or n-propyl p-hydroxybenzoate), one or more coloring agents, one or more flavoring agents, and one or more sweetening agents (e.g., sucrose, aspartame, or saccharin). The formulation may be adjusted for osmolality.

[0105] Also included are solid form preparations that are intended to be converted immediately before use into liquid form preparations for oral administration.Such liquid forms include solutions, suspensions and emulsions.These preparations may contain, in addition to the active ingredient, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizers, etc.

[0106] Oily suspensions can be formulated by suspending the compounds of the present invention in a vegetable oil (e.g., peanut oil, olive oil, sesame oil or coconut oil) or a mineral oil (e.g., liquid paraffin); or a mixture thereof. The oily suspensions can contain a thickening agent (e.g., beeswax, hard paraffin or cetyl alcohol). Sweetening agents (e.g., glycerol, sorbitol or sucrose) can be added to provide a palatable oral preparation. These preparations can be preserved by adding an antioxidant such as ascorbic acid. For an example of an injectable oily vehicle, see Minto, J. Pharmacol. Exp. Ther. 281:93-102, 1997. The pharmaceutical preparations of the present invention can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil, as described above, or a mixture thereof. Suitable emulsifying agents include naturally occurring gums (e.g., gum arabic and gum tragacanth), naturally occurring phosphatides (e.g., soybean lecithin), esters or partial esters derived from fatty acids and hexitol anhydrides (e.g., sorbitan mono-oleate) and condensation products of these partial esters with ethylene oxide (e.g., polyoxyethylene sorbitan mono-oleate). Emulsions may also contain sweetening and flavoring agents, as in the formulation of syrups and elixirs. Such formulations may also contain a demulcent, preservative, or coloring agent.

[0107] The compositions of the present invention can also be delivered as microspheres for slow release in the body. For example, microspheres can be formulated for administration via intradermal injection of drug-containing microspheres that slowly release subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995); as biodegradable injectable gel formulations (see, e.g., Gao Pharm. Res. 12:857-863, 1995); or as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol. 49:669-674, 1997). Both transdermal and intradermal routes provide constant delivery over weeks or months.

[0108] In another embodiment, the compositions of the present invention can be formulated for parenteral administration (e.g., intravenous (IV) administration or administration into a body cavity or lumen of an organ). Preparations for administration usually include a solution of the compositions of the present invention dissolved in a pharma- ceutically acceptable carrier. Acceptable vehicles and solvents that can be used are water and Ringer's solution, isotonic sodium chloride. In addition, sterile fixed oils can be conventionally used as a solvent or suspending medium. For this purpose, any bland fixed oil can be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be used in the preparation of injectables as well. These solutions are sterile and usually free of undesirable substances. These preparations can be sterilized by conventional, well-known sterilization procedures. They can contain pharma-ceutically acceptable auxiliary substances as required to approximate physiological conditions (e.g., pH adjusting and buffering agents, toxicity adjusting agents, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc.). The concentration of the composition of the present invention in these preparations can vary widely and can be selected mainly based on the volume of fluid, viscosity, body weight, etc., according to the specific mode of administration selected and the needs of the patient. For IV administration, the preparation can be a sterile injectable preparation (e.g., a sterile injectable aqueous or oily suspension). This suspension can be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent (e.g., a solution in 1,3-butanediol).

[0109] In another embodiment, in some embodiments, the formulation of the composition of the present invention can be delivered by using liposomes, which fuse with the cell membrane or are endocytosed, i.e., by using ligands attached to the liposomes or directly attached to oligonucleotides that bind to cell surface membrane protein receptors, resulting in endocytosis.The composition of the present invention can be delivered to target cells in vivo by using liposomes, particularly when the liposome surface has a ligand specific to the target cell or is otherwise preferentially directed to a specific organ (see, for example, Al-Muhammed, J. Microencapsul. 13:293-306, 1996; Chonn, Curr. Opin. Biotechnol. 6:698-708, 1995; Ostro, Am. J. Hosp. Pharm. 46:1576-1587, 1989).

[0110] The compositions of the present invention can be delivered by any suitable means, including oral, parenteral and topical. Topical routes of transdermal administration can be formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders and aerosols.

[0111] The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate amounts of the compound of the present invention. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation (for example, packaged tablets, capsules, and powders in vials or ampoules). Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or the appropriate number of any of these in packaged form.

[0112] The compounds of the present invention may be present in any suitable amount, which may depend on various factors, including but not limited to the weight and age of the subject, disease state, etc. Suitable dosage ranges of the compounds of the present invention include about 0.1 mg to about 10,000 mg, or about 1 mg to about 1000 mg, or about 10 mg to about 750 mg, or about 25 mg to about 500 mg, or about 50 mg to about 250 mg. Suitable dosages of the compounds of the present invention include about 1 mg, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 mg.

[0113] The compounds of the invention may be administered at any suitable frequency, interval and duration. For example, the compounds of the invention may be administered hourly, twice hourly, three or more times, once a day, twice a day, three or more times, or once every 2, 3, 4, 5, 6, or 7 days to provide a preferred dosage level. When the compounds of the invention are administered multiple times a day, representative intervals include 5, 10, 15, 20, 30, 45, and 60 minutes, and 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24 hours. The compounds of the invention may be administered once, twice, or three or more times for 1 hour, 1-6 hours, 1-12 hours, 1-24 hours, 6-12 hours, 12-24 hours, 1 day, 1-7 days, 1 week, 1-4 weeks, 1 month, 1-12 months, 1 year or more, or indefinitely.

[0114] The compositions may also include other compatible therapeutic agents. The compounds described herein may be used in combination with each other, with other active agents known to be useful in modulating the glucocorticoid receptor, or with adjuvants that may not be effective alone but may contribute to the effectiveness of the active agent.

[0115] The compound of the present invention may be co-administered with another active agent. Co-administration includes administration of the compound of the present invention and the active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20 or 24 hours of each other. Co-administration also includes administration of the compound of the present invention and the active agent simultaneously, nearly simultaneously (e.g., within about 1, 5, 10, 15, 20 or 30 minutes of each other) or sequentially in any order. Furthermore, the compound of the present invention and the active agent may each be administered once a day, or two, three or more times a day to provide a preferred daily dosage level.

[0116] In some embodiments, simultaneous administration may be achieved by co-formulation, i.e., preparing a single pharmaceutical composition that contains both the compound of the invention and the active agent, hi other embodiments, the compound of the invention and the active agent are formulated separately.

[0117] The compounds of the invention and the active agents may be provided in the compositions of the invention in any suitable weight ratio, such as about 1:100 to about 100:1 (w / w), or about 1:50 to about 50:1, about 1:25 to about 25:1, about 1:10 to about 10:1, or about 1:5 to 5:1 (w / w). The compounds of the invention and the other active agents may be provided in any suitable weight ratio, such as about 1:100 (w / w), 1:50, 1:25, 1:10, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 25:1, 50:1, or 100:1 (w / w). Other dosage amounts and dose ratios of the compounds of the invention and the active agents are suitable in the compositions and methods of the invention. V. Treatment Methods

[0118] In some embodiments, provided herein is a method of treating a disease or disorder, such as, but not limited to, a neurological disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention, or a pharma- ceutical acceptable salt thereof, thereby treating the disease or disorder.

[0119] In some embodiments, provided herein is a method of enhancing neuroplasticity, comprising contacting a neuronal cell with a compound of the present invention, or a pharma- ceutical acceptable salt thereof, in an amount sufficient to enhance neuroplasticity of the neuronal cell, wherein the compound causes the maximum number of dendritic intersections to increase by more than 1.0-fold according to Sholl analysis. Neuropathy

[0120] Neuronal plasticity and its changes are responsible for many neurological diseases and disorders. For example, during development and adulthood, changes in the number and morphology (e.g., length, intersection, density) of dendritic spines accompany the formation, maintenance, and elimination of synapses, and these changes are thought to establish and reconstruct connectivity within neural circuits. Furthermore, the structural plasticity of dendritic spines is coordinated with the function and plasticity of synapses. For example, the expansion of spines is coordinated with long-term potentiation in neural circuits, while long-term depression is associated with the shrinkage of spines.

[0121] Moreover, dendritic spines undergo experience-dependent morphological changes in living animals, and even subtle changes in dendritic spines can affect synaptic function, synaptic plasticity, and patterns of connectivity in neural circuits. For example, neurological diseases and disorders, such as neurodegenerative diseases and disorders (e.g., Alzheimer's disease and Parkinson's disease) and neuropsychiatric diseases and disorders (e.g., depression and schizophrenia), are accompanied by disease-specific perturbations in the shape, size, and / or number of dendritic spines, suggesting that dendritic spines serve as a common substrate in diseases involving impaired information processing.

[0122] Unless otherwise indicated, a neurological disease or disorder generally refers to a disease or disorder of an individual's central nervous system (CNS) (eg, brain, spine, and / or nerves).

[0123] In some embodiments, provided herein are methods of treating a neurological disease or disorder using a compound provided herein (e.g., a compound of Formula (K), Formula (J), Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), or a pharma- ceutically acceptable salt or solvate thereof).

[0124] In some cases, compounds provided herein are useful for treating various brain disorders and other conditions. In some embodiments, the compounds provided herein inhibit 5-HT 2A In some embodiments, 5-HT is a modulator that promotes neuroplasticity (e.g., plasticity of cortical structures). 2A Modulators (e.g., 5-HT 2A In some embodiments, the compounds provided herein are 5-HT 2C In some embodiments, 5-HT is a modulator that promotes neuroplasticity (e.g., plasticity of cortical structures). 2C The modulators are used to treat brain disorders. In some embodiments, the brain disorders include reduced neuroplasticity, reduced plasticity of cortical structures, 5-HT 2A Decreased receptor content, 5-HT 2C These include increased receptor content, decreased dendritic branching complexity, loss of dendritic spines, decreased dendritic branch content, decreased spine formation, decreased neurite formation, neurite retraction, or any combination thereof.

[0125] In one aspect, the compounds provided herein (e.g., a compound of Formula (K), Formula (J), Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), or a pharma- ceutically acceptable salt or solvate thereof) improve the number of dendritic spines and dendritic spine morphology lost in a neurological disease or disorder.

[0126] In some embodiments, the compounds of the invention are used to treat neurological disorders. In some embodiments, the compounds have, for example, anti-addictive, anti-depressant, anxiolytic properties, or a combination thereof. In some embodiments, the neurological disorder is a neuropsychiatric disorder. In some embodiments, the neuropsychiatric disorder is a mood or anxiety disorder. In some embodiments, the neurological disorder is a migraine, a headache (e.g., cluster headache), post-traumatic stress disorder (PTSD), anxiety, depression, a neurodegenerative disorder, Alzheimer's disease, Parkinson's disease, a psychiatric disorder, treatment-resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and addiction (e.g., substance use disorder). In some embodiments, the disorder is a headache disorder. In some embodiments, the neurological disorder is a migraine or a cluster headache. In some embodiments, the disorder is a migraine. In some embodiments, the disorder is a cluster headache. In some embodiments, the disorder is addiction. In some embodiments, the disorder is a substance use disorder. In some embodiments, the disorder is an alcohol use disorder. In some embodiments, the disease is an alcohol use disorder.

[0127] In some embodiments, the neurological disorder is a neurodegenerative disorder, Alzheimer's disease, or Parkinson's disease. In some embodiments, the neurological disorder is a psychiatric disorder, treatment-resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), depression, or anxiety. In some embodiments, the neuropsychiatric disorder is a psychiatric disorder, treatment-resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), depression, or anxiety. In some embodiments, the neuropsychiatric or neurological disorder is a post-traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), schizophrenia, depression, or anxiety. In some embodiments, the neuropsychiatric or neurological disorder is an addiction (e.g., substance use disorder). In some embodiments, the neuropsychiatric or neurological disorder is depression. In some embodiments, the neuropsychiatric or neurological disorder is anxiety. In some embodiments, the neuropsychiatric or neurological disorder is post-traumatic stress disorder (PTSD). In some embodiments, the neurological disorder is stroke or traumatic brain injury. In some embodiments, the neuropsychiatric or neurological disorder is schizophrenia.

[0128] In some embodiments, the disease is a neuropsychiatric disease, hi some embodiments, the disease is a neurodegenerative disease.

[0129] In some embodiments, the compounds of the present invention are used to treat brain disorders. In some embodiments, the compounds have, for example, anti-addictive, anti-depressant properties, anti-anxiety properties, or a combination thereof. In some embodiments, the brain disorder is a neuropsychiatric disorder. In some embodiments, the neuropsychiatric disorder is a mood or anxiety disorder. In some embodiments, the brain disorder includes, for example, migraine, cluster headache, post-traumatic stress disorder (PTSD), anxiety, depression, schizophrenia, and addiction (e.g., substance use disorder). In some embodiments, the brain disorder includes, for example, migraine, addiction (e.g., substance use disorder), depression, and anxiety.

[0130] In some embodiments, provided herein is a method of enhancing neuroplasticity, comprising contacting a neuronal cell with a compound of the present invention, or a pharma- ceutical acceptable salt thereof, in an amount sufficient to enhance neuroplasticity of the neuronal cell, wherein the compound causes the maximum number of dendritic intersections to increase by more than 1.0-fold according to Sholl analysis.

[0131] Neuroplasticity refers to the brain's ability to change structure and / or function throughout a subject's life. Throughout a subject's life, new neurons are generated and integrated into the central nervous system. Enhancement of neuroplasticity includes, but is not limited to, promoting neuronal growth, promoting neuritogenesis, promoting synaptogenesis, promoting dendrite formation, enhancing dendritic branching complexity, enhancing dendritic spine density, and increasing excitatory synapses in the brain. In some embodiments, enhancement of neuroplasticity includes promoting neuronal growth, promoting neuritogenesis, promoting synaptogenesis, promoting dendrite formation, enhancing dendritic branching complexity, and enhancing dendritic spine density.

[0132] In some embodiments, enhancing neuroplasticity can treat a neurodegenerative disorder, Alzheimer's disease, Parkinson's disease, psychiatric disorder, depression, addiction, anxiety, post-traumatic stress disorder, treatment-resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or substance use disorder. In some embodiments, the neuropsychiatric disorder is bipolar disorder. In some embodiments, the disease is depression. In some embodiments, the disease is a neurodegenerative disease. In some embodiments, the disease is Alzheimer's disease or Parkinson's disease. In some embodiments, the disease is Alzheimer's disease. In some embodiments, the disease is Parkinson's disease.

[0133] In some embodiments, the compounds of the present invention are used to enhance neuroplasticity. In some embodiments, the compounds used to enhance neuroplasticity have, for example, anti-addictive, anti-depressant properties, anxiolytic properties, or a combination thereof. In some embodiments, the decrease in neuroplasticity is associated with a neuropsychiatric disease. In some embodiments, the neuropsychiatric disease is a mood or anxiety disorder. In some embodiments, the neuropsychiatric disease includes, for example, migraine, cluster headache, post-traumatic stress disorder (PTSD), schizophrenia, anxiety, depression, and addiction (e.g., substance use disorder). In some embodiments, the brain disorder includes, for example, migraine, addiction (e.g., substance use disorder), depression, and anxiety. In some embodiments, the disease is a neuropsychiatric disease.

[0134] In some embodiments, the experiment or assay for determining an increase in neuronal plasticity of any compound of the present invention may include a phenotypic assay, a dendritogenesis assay, a neuritogenesis assay, a synaptogenesis assay, a Sholl analysis, a concentration-response experiment, a 5-HT 2A Agonist assay, 5-HT 2A Antagonist assay, 5-HT 2A Binding assay, or 5-HT 2A Blocking Experiments (eg, Ketanserin Blocking Experiments). In some embodiments, an experiment or assay for determining the hallucinogenic potential of the compounds provided herein is a mouse head twitch response (HTR) assay.

[0135] The compounds of the present invention are 5-HT 2A In some embodiments, the compounds of the present invention have activity as 5-HT 2A In some embodiments, the compounds of the present invention have activity as 5-HT 2A Activate the receptor (e.g., allosteric modulation or 5-HT 2A They induce biological responses by activating 5-HT receptors (modulating biological targets). 2AAgonism has been associated with promoting neuroplasticity. 2A The sensor assay is in an agonist mode or an antagonist mode. 2A The sensor assay is in agonist mode.

[0136] In some embodiments, the compounds described herein are selective 5-HT 2A In some embodiments, the compounds described herein are 5-HT 2A In some embodiments, the compounds described herein are selective 5-HT 2A It is a modulator and promotes neuroplasticity (e.g., cortical structural plasticity). In some embodiments, promotion of neuroplasticity includes, for example, enhanced dendritic spine growth, increased synthesis of synaptic proteins, enhanced synaptic response, enhanced dendritic branching complexity, enhanced dendritic branching content, enhanced spine formation, enhanced neurite formation, or any combination thereof. In some embodiments, enhanced neuroplasticity includes, for example, enhanced cortical structural plasticity in the anterior part of the brain.

[0137] In some embodiments, the non-hallucinogenic 5-HT 2A Modulators (e.g., 5-HT 2A In some embodiments, non-hallucinogenic 5-HT agonists are used to treat the disease. 2A Modulators (e.g., 5-HT 2A In some embodiments, non-hallucinogenic 5-HT agonists are used to enhance neuroplasticity. 2A Modulators (e.g., 5-HT 2A agonists) are used to enhance neuroplasticity and dendritic spine density.

[0138] In some embodiments, the experiment or assay for determining an increase in neuronal plasticity of any compound of the present invention may include a phenotypic assay, a dendritogenesis assay, a neuritogenesis assay, a synaptogenesis assay, a Sholl analysis, a concentration-response experiment, a 5-HT 2C Agonist assay, 5-HT 2C Antagonist assay, 5-HT 2C Binding assay, or 5-HT 2C Blocking Experiments (eg, Ketanserin Blocking Experiments). In some embodiments, an experiment or assay for determining the hallucinogenic potential of the compounds provided herein is a mouse head twitch response (HTR) assay.

[0139] The compounds of the present invention are 5-HT 2C In some embodiments, the compounds of the present invention have activity as 5-HT 2C In some embodiments, the compounds of the present invention have activity as 5-HT 2C Activate the receptor (e.g., allosteric modulation or 5-HT 2C They induce biological responses by activating 5-HT receptors (modulating biological targets). 2C Agonism has been associated with promoting neuroplasticity. 2C The sensor assay is in an agonist mode or an antagonist mode. 2C The sensor assay is in agonist mode.

[0140] In some embodiments, the compounds described herein are selective 5-HT 2C In some embodiments, the compounds described herein are 5-HT 2C In some embodiments, the compounds described herein are selective 5-HT 2CIt is a modulator and promotes neuroplasticity (e.g., cortical structural plasticity). In some embodiments, promotion of neuroplasticity includes, for example, enhanced dendritic spine growth, increased synthesis of synaptic proteins, enhanced synaptic response, enhanced dendritic branching complexity, enhanced dendritic branching content, enhanced spine formation, enhanced neurite formation, or any combination thereof. In some embodiments, enhanced neuroplasticity includes, for example, enhanced cortical structural plasticity in the anterior part of the brain.

[0141] In some embodiments, the non-hallucinogenic 5-HT 2C Modulators (e.g., 5-HT 2C In some embodiments, non-hallucinogenic 5-HT agonists are used to treat the disease. 2C Modulators (e.g., 5-HT 2C In some embodiments, non-hallucinogenic 5-HT agonists are used to enhance neuroplasticity. 2C Modulators (e.g., 5-HT 2C agonists) are used to enhance neuroplasticity and dendritic spine density.

[0142] In some embodiments, provided herein is a method of enhancing neuroplasticity and increasing dendritic spine density, comprising contacting a neuronal cell with a compound of the present invention, or a pharma- ceutical acceptable salt thereof, in an amount sufficient to enhance neuroplasticity and increase dendritic spine density of the neuronal cell.

[0143] Dendritic spines are dynamic and can change significantly in density, shape, and volume over time. The growth or loss of dendritic spines, which can contribute to dendritic spine density, may be important for reinforcing neural pathways for learning, memory, and general cognitive function. Enhancement of dendritic spine density may be useful in the treatment of neurological disorders, including, but not limited to, neurodegenerative and neuropsychiatric disorders.

[0144] The increase in dendritic spine density can be measured by staining methods or immunocytochemical methods known to those skilled in the art, including but not limited to electron microscopy, Golgi staining, crystal violet staining, DAPI staining, and eosin staining. For example, Golgi staining can be used to measure dendritic spine density.

[0145] In some embodiments, the compounds provided herein, or pharma- ceutically acceptable salts thereof, are useful for promoting neuronal growth and / or improving neuronal structure.

[0146] In some embodiments, the compounds provided herein, or pharma- ceutically acceptable salts thereof, are non-hallucinogenic psychoplastogens useful for treating one or more diseases or disorders associated with loss of synaptic connectivity and / or plasticity.

[0147] In some embodiments, an individual administered a compound provided herein does not experience a hallucinogenic event (at any time after administration of the compound to the individual).

[0148] In some embodiments, provided herein are methods for treating a disease or disorder in an individual in need thereof, wherein the disease or disorder is a neurological disease or disorder.

[0149] In some embodiments, provided herein are compounds (e.g., pharma- ceutically acceptable salts or solvates thereof) useful for modulating the 5-hydroxytryptamine (5-HT) receptor. In some embodiments, the 5-HT receptor modulated by the compounds provided herein is the 5-hydroxytryptamine receptor 2A (5-HT 2A In some embodiments, the 5-HT receptor modulated by the compounds provided herein is the 5-hydroxytryptamine receptor 2C (5-HT 2C ).

[0150] In some embodiments, 5-HT 2A and 5-hydroxytryptamine receptor 2A (5-HT 2A Provided herein are modulators of 5-HT 2C and 5-hydroxytryptamine receptor 2C (5-HT 2C Modulators of are provided herein.

[0151] In some embodiments, the compounds provided herein, or pharma- ceutically acceptable salts thereof, are used in the preparation of a medicament for the treatment of a disease or disorder in a mammal that would benefit from the inhibition or reduction of 5-HT2A activity.

[0152] In some embodiments, the compounds provided herein, or pharma- ceutically acceptable salts thereof, are used in the preparation of a medicament for the treatment of a disease or disorder in a mammal that would benefit from promoting neuronal growth and / or improving neuronal structure.

[0153] Methods for treating any of the diseases or disorders described herein in a mammal in need of such treatment include administering to said mammal a therapeutically effective amount of at least one compound described herein, or a pharma- ceutically acceptable salt, active metabolite, prodrug, or pharma- ceutically acceptable solvate thereof.

[0154] In certain embodiments, compositions containing the compounds described herein are administered for preventive and / or therapeutic treatment. In certain therapeutic applications, the compositions are administered to a mammal already suffering from a disease or condition in an amount sufficient to cure or at least partially prevent at least one of the symptoms of the disease or condition. Amounts effective for this use depend on the severity and course of the disease or condition, previous treatments, the mammal's health status, weight, and response to the drug, and the judgment of a medical professional. Therapeutically effective amounts are optionally determined by methods including, but not limited to, dose escalation and / or dose-finding clinical trials.

[0155] In prophylactic applications, compositions containing the compounds described herein are administered to a mammal susceptible to or at risk of a particular disease, disorder, or condition. Such an amount is defined as a "prophylactically effective amount or dose." In this application, the exact amount also depends on the condition, weight, etc. of the mammal. When used in a mammal, the effective amount for this application will depend on the severity and course of the disease, disorder, or condition, previous treatments, the mammal's health status and response to the drug, and the judgment of the medical practitioner. In some embodiments, prophylactic treatment involves administering a compound described herein or a pharma- ceutical acceptable salt thereof to a mammal that has previously experienced at least one symptom of the disease being treated and is now in remission, to prevent the recurrence of the disease or condition.

[0156] In some embodiments where the mammal's condition does not improve, at the discretion of the medical practitioner, administration of the compound is administered chronically, i.e., for an extended period of time, including the lifetime of the mammal, to ameliorate or otherwise inhibit or limit the symptoms of the disease or disorder in the mammal.

[0157] In some embodiments where the condition of the mammal is improved, the dose of the drug being administered is temporarily reduced or temporarily stopped for a period of time (i.e., a "drug holiday"). In some embodiments, the length of the drug holiday is between 2 days and 1 year, such as, by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, or more than 28 days. The reduction in dose during the drug holiday is, by way of example only, 10% to 100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.

[0158] Once improvement of the patient's condition has occurred, a maintenance dose is administered as necessary. Thereafter, in certain embodiments, the dosage or frequency of administration, or both, depending on the symptoms, is reduced to a level at which the improved disease, disorder, or condition is maintained. In some embodiments, however, the mammal will require intermittent treatment on a long-term basis upon recurrence of symptoms.

[0159] The amount of a given drug that corresponds to such an amount will vary depending on factors such as the particular compound, the disease state and its severity, the identity of the subject or host requiring treatment (e.g., weight, sex), etc., but will nevertheless be determined by the particular circumstances surrounding the case, including, for example, the particular drug being administered, the route of administration, the disease being treated, and the subject or host being treated.

[0160] In general, however, dosages used for adult human treatment typically range from 0.01 mg to 5000 mg per day. In some embodiments, dosages utilized for adult human treatment are from about 1 mg to about 1000 mg per day. In some embodiments, the desired dosage is suitably presented as a single dose or as divided doses administered simultaneously or at appropriate intervals, for example, as two, three, four or more subdoses per day.

[0161] In some embodiments, a suitable daily dosage of the compounds described herein or pharma- ceutically acceptable salts thereof is about 0.01 to about 50 mg per kg of body weight. In some embodiments, the amount of active ingredient in the daily dosage or dosage form will be less than or greater than the ranges set forth herein, based on many variables related to the individual treatment regimen. In some embodiments, the daily dosage and unit dosage will vary depending on many variables, including, but not limited to, the activity of the compound used, the disease or condition being treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the physician's judgment.

[0162] Toxicity and therapeutic efficacy of such treatment regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, determination of LD50 and ED50. The dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD50 and ED50. In some embodiments, data obtained from cell culture assays and animal studies are used in formulating a therapeutically effective daily dose range and / or a therapeutically effective unit dose for use in mammals, including humans. In some embodiments, the daily dose of the compounds described herein falls within a range of circulating concentrations that includes the ED50 with minimal toxicity. In some embodiments, the daily dose range and / or unit dose varies within this range depending on the dosage form used and the route of administration utilized.

[0163] In any of the foregoing aspects, in further embodiments, an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, is (a) administered systemically to a mammal, and / or (b) administered orally to a mammal, and / or (c) administered intravenously to a mammal, and / or (d) administered by injection to a mammal, and / or (e) administered locally to a mammal, and / or (f) administered non-systemically or locally to a mammal.

[0164] In any of the foregoing aspects, there are further embodiments that include a single administration of an effective amount of the compound, including further embodiments in which (i) the compound is administered once daily, or (ii) the compound is administered multiple times throughout the day to the mammal.

[0165] In any of the foregoing aspects, there are further embodiments that include multiple administrations of an effective amount of the compound, including further embodiments where (i) the compound is administered continuously or intermittently, such as in a single dose, (ii) the interval between multiple doses is every 6 hours, (iii) the compound is administered to the mammal every 8 hours, (iv) the compound is administered to the mammal every 12 hours, or (v) the compound is administered to the mammal every 24 hours. In further or alternative embodiments, the method includes a drug holiday, where administration of the compound is temporarily suspended or the amount of compound being administered is temporarily reduced, and at the end of the drug holiday, administration of the compound is resumed. In one embodiment, the length of the drug holiday varies from 2 days to 1 year.

[0166] In some embodiments, the therapeutic effectiveness of one of the compounds described herein is enhanced by administration of an adjuvant (i.e., the adjuvant has minimal therapeutic benefit by itself, but when combined with another therapeutic agent, enhances the overall therapeutic benefit to the patient). Alternatively, in some embodiments, the benefit experienced by the patient is increased by administering one of the compounds described herein with another agent (including a treatment regimen) that also has a therapeutic effect.

[0167] In some embodiments, various therapeutically effective amounts of the compounds disclosed herein are utilized in formulating pharmaceutical compositions and / or in treatment regimens in which the compounds disclosed herein are administered in combination with one or more additional agents, such as additional therapeutically effective drugs, adjuvants, etc. The therapeutically effective amounts of drugs and other agents used in combination therapy regimens are optionally determined by means similar to those specified above for the active ingredients themselves. Additionally, the prevention / treatment methods described herein include the use of metronomic dosing, i.e., providing more frequent, lower doses to minimize toxic side effects. In some embodiments, combination therapy regimens include treatment regimens in which administration of the compounds described herein, or pharma- ceutically acceptable salts thereof, is initiated before, during, or after treatment with a second agent described herein, and continues at any time during or after the end of treatment with the second agent. A combination therapy regimen includes treatments in which a compound described herein, or a pharma- ceutically acceptable salt thereof, and a second agent used in combination are administered at the same time or at different times and / or at intervals of increasing or decreasing duration of treatment. Combination therapy also includes periodic treatments that are started and stopped at various times to aid in the clinical management of the patient.

[0168] It will be understood that the dosage regimen to treat, prevent, or ameliorate the disease for which relief is sought will be modified to accommodate a variety of factors, such as the disease or disorder from which the subject suffers, the subject's age, weight, sex, diet, and medical condition. Thus, in some instances, the dosage regimen actually utilized will vary and, in some embodiments, will deviate from the dosage regimens set forth herein. EXAMPLES

[0169] VI. Working Examples Detailed Method Data analysis and statistics. Treatments were randomized and data were analyzed by an experimenter blinded to treatment condition. Statistical analyses were performed using GraphPad Prism (version 9.1.2) unless otherwise noted. All comparisons were planned before each experiment was performed. Data are presented as mean ± SEM, with asterisks indicating *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001, unless otherwise noted.

[0170] Molecular docking. Docking of (+)-JRT to 5-HT2AR was performed using Autodock Vina (version 1.1.2) and docking the previously published structure of 5-HT2AR to LSD (PDB:7wc6). First, the existing ligands of the published structure (i.e., LSD) were removed from the protein. Then, (+)-JRT was docked at the known active site according to the specified parameters. The binding pocket search area was defined as a 40x40x40 grid with 0.375 Å spacing at coordinates x=-28, y=-11, z=142 as indicated by MGL AutoDockTools (version 1.5.7) with exhaustiveness setting of 20. The generated conformation was analyzed and exported using MGL AutoDockTools (version 1.5.7). The (+)-JRT PDB structure was generated by conversion of the ChemDraw structure using UCSF Chimera. A 3D image of the binding site was generated using UCSF Chimera (version 1.16) from the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIH P41 RR-01081).

[0171] Drugs. Many of the drugs used in these studies were purchased from commercial suppliers, including D-amphetamine sulfate (Sigma Aldrich, 1180004), ketamine hydrochloride (Spectrum, K1068), and ketanserin (APExBIO, B2248). Lysergic acid diethylamide (LSD) hemitartrate was generously provided by the NIH Drug Supply Program. Both (+)-JRT and (-)-JRT were synthesized in-house and judged to be analytically pure based on NMR and LC-MS data. For cell culture experiments, VEH = 0.1% (agonist studies) or 0.2% (antagonist studies) molecular biology grade dimethyl sulfoxide (Sigma-Aldrich). For in vivo experiments, compounds were administered ip at 5 mL / kg using 0.9% saline as the vehicle unless otherwise noted. VEH = USP grade saline (0.9%). For all cellular experiments the free base was used whereas for in vivo studies the fumarate salts of (+)-JRT and (-)-JRT were used. Stock solutions for behavioral assays were freshly prepared before use.

[0172] Animals. All experimental procedures involving animals were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California, Davis, the Salk Institute, Weill Cornell Medicine, or the Contract Research Organization (CRO) where the study was performed. All procedures involving animals adhered to the principles outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Animals were obtained from Jackson Laboratory (Sacramento, CA) or bred in-house unless otherwise noted. Power analyses were performed to ensure adequate sample sizes for all experiments involving animals. Animals were housed with 2–5 animals of the same sex per cage and had free access to food and water unless otherwise noted. Lights in the vivarium were turned on at 07:00 and off at 19:00. The University of California, Davis, the Salk Institute and Weill Cornell Medicine are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

[0173] Radioligand binding selectivity panel. Competitive radioligand binding for (+)-JRT (10 μM) and (-)-JRT (10 μM) was performed across a panel of receptors at Eurofins Discovery. LSDK i Values ​​were obtained from reports and, whenever possible, matched in origin to the receptor radioligand.

[0174] Radioligand binding studies (5-HT2AR and 5-HT2CR). Competitive radioligand binding assays for 5-HT2AR and 5-HT2CR were performed at Epics Therapeutics SA (Belgium, FAST-0505B) using conventional methods. Briefly, competitive binding was performed using binding buffer, membrane extracts, radiotracer [ 3 H]-DOI and test compounds were carried out in duplicate in wells of a 96-well plate (Master Block, Greiner, 786201). Non-specific binding was measured by co-incubation with a 200-fold excess of non-radioactive competitor DOI. Samples were incubated in a final volume of 0.1 mL for temperatures and durations optimized for either 5-HT2AR or 5-HT2CR, then filtered through a filtration plate. Filters were washed six times with 0.5 ml of ice-cold wash buffer (optimized for 5-HT2AR), and 50 μl of Microscint20 (Packard) was added to each well. The plates were incubated for 15 min on an orbital shaker, then counted in a TopCount™ for 1 min / well.

[0175] Radioligand binding studies (5-HT2BR). Competitive radioligand binding studies for 5-HT2BR were performed at Eurofins Cerep SA (Celle l'Evescault, France) using conventional methods (catalog #1333).

[0176] IP1 Assay (5-HT2AR and 5-HT2CR). IPOne HTRF assays for 5-HT2AR and 5-HT2CR were performed at Epics Therapeutics SA (Belgium, FAST-0505I) using conventional methods. Briefly, CHO-K1 cells expressing human recombinant 5-HT2AR, cultured to mid-logarithmic phase in antibiotic-free medium, were detached with PBS-EDTA, centrifuged, and resuspended in antibiotic-buffer-free medium. 20,000 cells were then dispersed in a 96-well plate and incubated overnight at 37°C with 5% CO2. For agonist testing, the medium was removed and 20 μl of assay buffer + 20 μl of test compound or reference agonist (α-Me-5-HT) was added to each well. The plate was incubated for 60 min at 37°C with 5% CO2. After addition of lysis buffer containing IP1-d2 and anti-IP1 cryptate detection reagent, the plates were incubated for 1 h at room temperature and the fluorescence ratio was measured using the HTRF kit according to the manufacturer's specifications.

[0177] IP1 Assay (5-HT2BR). The 5-HT2BR IP1 assay was performed at Eurofins Cerep SA (Celle l'Evescault, France) using conventional methods (catalog #3344).

[0178] β-Arrestin Activation (PathHunter®). The 5-HT2AR PathHunter® β-arrestin agonist assay was performed on a Eurofins DiscoverX (Frement, CA, Catalog # 86-0001P-2090AG). The PathHunter® β-arrestin assay uses a technology developed by DiscoverX called Enzyme Fragment Complementation (EFC) to monitor GPCR activation in a homogenous, non-imaging assay format, using β-galactosidase (βGal) as a functional reporter. The enzyme is split into two inactive complementary parts: a small peptide called ProLink™ (PK) and a larger protein called Enzyme Acceptor (EA). The PK and EA are then expressed as fusion proteins in U2OS cells, with the PK fused to the GPCR of interest and the EA fused to β-arrestin. When the target GPCR is activated and β-arrestin is recruited to the receptor, PK and EA complementation occurs, restoring β-Gal activity that is measured using chemiluminescent PathHunter® Detection Reagents.

[0179] PsychLight Assay. Psychlight assay was performed using a previously published method. Briefly, glass-bottom 96-well plates were coated with 50 μg / mL poly-D-lysine overnight at room temperature and then washed with Dulbecco's PBS. PSYLI2 cells were suspended in DMEM containing 10% FBS with 5% penicillin-streptomycin, plated at a density of 40,000 cells / well, and incubated (37° C., 5% CO2) for 24 hours before each experiment. Just before the experiment, drug stock solutions in DMSO were diluted 1:100 in imaging medium spread across an empty 96-well plate (treatment plate), followed by randomization of the plate map. Imaging medium consisted of 1×HBSS containing 0.5 M MgCl2 and 5 M CaCl2. Cells cultured in separate 96-well plates were gently washed three times with imaging medium and the wells were filled with imaging medium. All imaging and incubations (both agonist and antagonist modes) were performed at ambient atmosphere and temperature. Data were from two plates with 2-3 wells analyzed per plate. VEH treatment conditions were normalized to 0% ΔF / F.

[0180] In agonist mode experiments, 180 μL of imaging medium was added to each well containing PSYLI2 cells. The wells were then imaged with a Thermofisher CellInsight CX7HCS Platform at 40× (NA=0.6). Regions of interest (ROIs) followed the default ROI pattern for each well with no position bias and no overlap of the ROIs (exposure=400ms, LED power=100%). Then, 20 μL from the treatment plate was transferred to the PSYLI2 cell-containing plate to obtain a final dilution of 1:1000. 5-HT (10 μM), ketanserin (10 μM), and DMSO (0.1%) were used as positive, negative, and vehicle controls, respectively. After 5 min of incubation, the same ROIs were reimaged using the same settings.

[0181] Once imaging was complete, the images were exported and analyzed using a custom Python script. Briefly, segmentation was performed on each image and a mask was created that highlighted the membrane of the HEK293T cells. The mask was created by calculating the mean fluorescence intensity of the entire image and using that value as a threshold. Pixels with intensity above the threshold were included in the mask. Pixel intensities were obtained from the mask-highlighted regions and then used to calculate %ΔF / F and exported to Excel. The %ΔF / F value for each well was calculated using the following equation:

number

[0182] In antagonist mode experiments, 160 μL of imaging medium was added to each well of the assay plate. The wells were then imaged with a CellInsight CX7HCS Platform at 40× (NA=0.6). The ROIs followed the default ROI pattern for each well with no position bias and no overlap of the ROIs (exposure=400ms, LED power=100%). A 100 μM stock solution of 5-HT in DMSO was then diluted 1:100 with imaging buffer. 20 μL of this solution was then added to the PSYLI2 cell-containing plate for a final concentration of 111 nM 5-HT (0.1% DMSO). The same ROI was imaged after 5 minutes of incubation. 20 μL from the treatment plate was then transferred to the PSYLI2 cell-containing plate for a final dilution of 1:1000 (0.2% DMSO). After 5 min of incubation, the same ROI was re-imaged using the same settings.

[0183] Once imaging was complete, the images were exported and analyzed using a custom Python script. Briefly, segmentation was performed on each image and a mask was created that highlighted the membrane of the HEK293T cells. The mask was created by calculating the mean fluorescence intensity of the entire image and using that value as a threshold. Pixels with intensity above the threshold were included in the mask. Pixel intensities were obtained from the mask-highlighted regions and then used to calculate %ΔF / F and exported to Excel. The %ΔF / F value for each well was then calculated using the following equation:

number

[0184] Dendritic formation in vivo. Female C57BL / 6J mice (Jackson Laboratory, Sacramento, CA) were treated with VEH (saline) or (+)-JRT (n=3 / group). After 24 hours, animals were sacrificed by transcardial perfusion of oxygenated Ringer's solution followed by perfusion with fixative (2% paraformaldehyde, 2.5% glutaraldehyde, 3 mM calcium chloride in 0.1 M cacodylate buffer). Brains were carefully removed from the skull and post-fixed overnight in the same fixative. Brains were then rinsed with PBS and 100 μm coronal sections through the prefrontal cortex were collected using a vibrating microtome (Leica). Regions of the infralimbic cortex were microdissected according to the Allen brain atlas and further processed for electron microscopy. Briefly, samples were stained with 1.5% reduced osmium tetroxide for 45 min, rinsed thoroughly, further stained with 1% aqueous uranyl acetate overnight at 4°C, dehydrated, and embedded in Eponate 12 epoxy resin. Block surfaces spanning from the medial cortical surface to the corpus callosum were trimmed, and 150-250 serial ultrathin sections (55 nm) were collected on silicon chips using a diamond knife (Diatome) with an ultramicrotome (Leica). The serial sections on the silicon chips were incorporated into a scanning electron microscope (SEM; Zeiss Sigma VP) for imaging. The apical hair region was identified, and a series of images were collected from the area of ​​interest identified on the serial sections. Following image alignment (achieved using SWiFT-IR through 3dem.org), the dataset for each animal comprised a volume of at least 20 × 20 × 10 μm with dimensions of a voxel size of 8 × 8 × 55 nm. Eight random dendrite cross sections were sampled from the central part of each volume. The dendrite midlines and dendritic spine skeletons were traced by two experts in VAST Lite software. Dendritic spine density (spines / μm) was calculated for each volume.

[0185] Head Twitch Response Assay. HTR assays were performed using equal numbers of male and female C57BL / 6J mice. Mice were obtained from Jackson Laboratory (Sacramento, CA) and were approximately 8-12 weeks old at the time of the experiment. After compound administration, animals were placed in an empty arena (40 cm × 40 cm) and filmed for 20 min. Between tests, the arena was cleaned with 70% ethanol. Animals were given a 1-week washout period before being retested. Animals were tested a maximum of four times. All drug treatments were randomized, and no animals received the same drug and dose twice. For blocking experiments, animals were administered (+)-JRT (1 mg / kg) or vehicle (saline) by IP injection and placed in an empty cage for 15 min. Animals were then administered LSD (0.2 mg / kg, IP), placed in the test arena, and filmed for 20 min. The videos were then scored by two blinded observers and the results were averaged (Pearson correlation coefficient >0.9).

[0186] Amphetamine-induced locomotion. Amphetamine-induced hyperlocomotor activity assays were performed using male and female C57BL / 6J mice that were approximately 8 weeks old at the time of the experiment. First, animals were placed in the test arena (40 cm x 40 cm) for 15 min to obtain baseline measurements of locomotion and to habituate the animals to the test arena. Next, animals were administered (+)-JRT (1 mg / kg) or VEH (2.5 mL / kg, ip) and placed back into the test arena. After 15 min, animals were administered D-amphetamine (3 mg / kg) or VEH (2.5 mL / kg) and placed back into the test arena for 60 min. Locomotion throughout the experiment was quantified using the ANYmaze Video Tracking System, version 7.07 (Stoelting Co.).

[0187] Rat Forced Swim Test (FST). This test was performed by Psychogenics (Paramus, NJ). Male Sprague-Dawley rats were purchased from Envigo (Indianapolis, IN) and, upon receipt, were assigned unique identification numbers (tail marked) and group-housed in ventilated cages with three rats per cage. All animals were maintained in group-housed groups of three for the remainder of the study. All rats were acclimated to the colony room for up to one week prior to dosing. During the acclimation period, rats were experimented on and handled daily and weighed to ensure proper health and suitability. Room temperature was maintained between 20°C and 23°C with a relative humidity of 30% to 70%. Lab Rodent Diet 5001 (WF Fisher, Cat # 11015) and water were provided ad libitum. Animals were randomly assigned across treatment groups. All tests were performed during the light phase of the light / dark cycle. The behavioral tests were performed according to a set protocol approved by the IACUC committee and PGI Standard Operation Procedures (SOP). Each forced swim chamber was constructed of clear acrylic (height = 40 cm; diameter = 20.3 cm). Only one rat was placed in the swim chamber at a time for each swim test. The water was replaced and the chamber was cleaned for each animal. The water depth was 16 cm in the first swim session (pre-test) and 30 cm in the second swim session (test). The water was maintained at 23°C ± 1°C throughout all swim sessions. At the end of each swim test, the rats were dried with paper towels and returned to their home cages. To ensure the safety of the animals in the swim tests, all animals were carefully observed, and all animals that could not maintain a position with their nose above the water were immediately removed from the water and were not further used in the test. First, the animals were subjected to a 15-min pre-test. Immediately after the pre-test, they were administered the compounds or VEH by ip injection (1 ml / kg). Racemic ketamine hydrochloride (10 mg / kg) was used as a positive control. A salt correction factor of 1.36 was used when preparing formulations of (+)-JRT to ensure a dose corresponding to that of the free base.A second FST was performed 24 hours after compound administration. The test lasted 5 minutes and was video recorded. A blinded experimenter manually scored the videos for swimming, climbing, and immobility behaviors. Scoring of the forced swim test was performed by trained technicians using a time-sample technique, observing animals in the video-recorded test every 5 seconds and recording the behaviors observed (e.g., immobility, swimming, or climbing). A total of 60 behaviors were recorded per subject per session.

[0188] 4-Odor discrimination and reversal. 4-Odor discrimination and reversal behavioral assays were performed as previously described with minor modifications. Food restriction was initiated 5 days prior to discrimination and reversal testing to reduce the animals' body weight to ∼80% of their starting weight. A total of 31 2-3 month old C57BL / 6J mice were used in this assay. Eleven mice (5 males, 6 females) were treated as VEH / non-stressed controls, 10 animals (4 males, 6 females) were treated as VEH / stressed groups, and 10 animals (4 males, 6 females) were treated as treated / stressed groups. Both VEH / stressed and VEH / treated groups were subjected to a 7-day unpredictable mild stress protocol using previously validated stressors. Two stressors were applied during the day, with an additional nocturnal stressor on 4 of those days. Briefly, the following stressors were used: Day 1: AM = predator odor (order) 30 min, PM = instability (moist bedding + tilt 30 min), night = tilted cage; Day 2: AM = overcrowding / social interaction (30 min), PM = restraint stress (30 min), night = none; Day 3: AM = restraint stress (30 min), PM = predator odor (30 min), night = none; Day 4: AM = exposure to novel room (30 min). ) + tail suspension (6 min), PM = restraint stress (30 min), night = tilted cage; day 5: AM = instability (moist bedding + tilt 30 min), PM = overcrowding / social interaction (30 min), night = none; day 6: AM = white noise / room change, PM = instability (moist bedding + tilt 30 min), night = tilted cage; day 7: AM = restraint stress (30 min), PM = overcrowding / social interaction (30 min), night = exposure to light.

[0189] Following unpredictable mild stress, animals underwent habituation / shaping / training on days 7 and 8 prior to discrimination and reversal testing on day 9. The behavioral apparatus was a 12" x 12" x 9" (length x width x height) opalescent acrylic box with four quadrants and a 3" long clear acrylic inner wall in the center of each outer wall to create a 6" diameter clear cylinder that was attached to the center of the box. On the first training day (day 7), mice were habituated to the apparatus and four 4 oz white ceramic pots (Yachi, www.amazon.com) placed in each corner of one quadrant of the box with a piece (~0.015g) of Honey Nut Cheerio (General Mills, Golden Valley, MN) as a food reward inside. For this first day of habituation, mice were placed in the center cylinder, which was then removed to begin each round of habituation; mice were allowed to freely explore until all four pots of food rewards were consumed or 10 min had elapsed. Mice were then returned to the cylinder and re-fed pots as needed for a total of six rounds of habituation throughout day 1.

[0190] On the second training day (day 8), VEH (saline) or (+)-JRT (1 mg / kg) was administered by IP injection. After a short recovery period, formation was performed with one pot. Food rewards were provided with increasing amounts of pine shavings (Living World, www.amazon.com) covering the food so that the mice had to dig to obtain the reward. The pot was moved between the four quadrants of the apparatus so that each location was equally rewarded; after finding and consuming the food reward, the mice were returned to the central cylinder between trials. Trials began with placing the food reward in the empty dish (4 trials), followed by dusting the added pine bedding (4 trials), followed by trials of filling the dish with pine shavings to a quarter (4 trials), half (4 trials) and full (12 trials).

[0191] On the test day (day 9), the four pots were filled with pine shavings and contained a piece of filter paper odorized with a drop of essential oil (LorAnn Oils, Lansing, MI) affixed to the inside rim. Rosemary, thyme, clove, and nutmeg were used in the early discrimination phase, with rosemary serving as the reward odor indicating the pot containing the food reward. Mice were placed in the center cylinder and then allowed to explore the arena after the cylinder was removed at the beginning of each trial. A trial ended when the mouse found and ate the food reward, began digging in the unrewarded pot, or after 3 min had elapsed without digging. The mouse was then returned to the center cylinder and, if necessary, refed in the rewarding pot, and the pots were rearranged so that no pot remained in the same quadrant during successive trials. Trials in which no digging was observed were recorded as misses; after two consecutive misses, a pot with pine shavings and a food reward placed in a well within the shavings was placed in the central cylinder to reinforce digging. The mouse passed this discrimination phase when it successfully located and ate the food reward in 8 out of 10 consecutive trials. Immediately after discrimination, the pine shavings were replaced in all pots and the thyme odorant was replaced with a novel cinnamon odorant. The reward odorant was changed from rosemary to clove. The mouse was again considered to have passed this reversal phase after successfully locating and consuming the food reward in 8 out of 10 consecutive trials. Materials and Methods

[0192] All reagents were obtained from commercial suppliers and reactions were carried out using oven-dried glassware (120°C) under an inert N2 atmosphere unless otherwise noted. Air- and moisture-sensitive liquids and solutions were transferred via syringe or stainless steel cannula. Organic solutions were concentrated under reduced pressure (~5 Torr) by rotary evaporation. Solvents were purified by passing through activated alumina columns under 12 psi of N2. Chromatography was performed using Fisher Chemical™ silica gel sorbent (230-400 mesh, grade 60). Compounds purified by chromatography were usually applied to the sorbent bed using the solvent conditions indicated with a minimal amount of additional dichloromethane as necessary for solubility. Thin-layer chromatography (TLC) was performed on Merck silica gel 60 F254 plates (250 μm). Visualization of developed chromatograms was achieved by fluorescence quenching or by staining with aqueous potassium permanganate or Ehrlich's reagent.

[0193] Nuclear magnetic resonance (NMR) spectra are 1 H and 13 C were acquired on a Bruker 400 operating at 400 and 100 MHz and were internally referenced to the residual solvent signal. 1 H NMR data were recorded as follows: chemical shift (δ, ppm), multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; quint, quintet; m, multiplet), coupling constant (Hz), and integral. 13 C NMR data are reported in terms of chemical shifts (δ, ppm). Infrared spectra were recorded using a Thermo Nicolet iS10 Fourier Transform Infrared (FTIR) spectrometer equipped with a Smart iTX Accessory (Diamond Attenuated Total Reflection (ATR)) and are reported in frequencies of absorption (ν, cm -1 ). Liquid chromatography-mass spectrometry (LC-MS) was performed using a Waters LC-MS equipped with an ACQUITY Arc QDa detector. Example 1: Preparation of N,N-diethyl-8-methyl-7a,8,9,10-tetrahydro-7H-indolo[7,1-fg][1,7]naphthyridine-10-carboxamide (14, major diastereomer, (±)-JRT) [ka] 3-Bromo-5-(diethylcarbamoyl)pyridine 1-oxide (3) [ka]

[0194] To a mixture of 5-bromonicotinic acid (10.000 g, 49.503 mmol, 1.0 equiv) in DCM (250 mL) cooled to 0° C. was slowly added oxalyl chloride (6.37 mL, 74.2 mmol, 1.5 equiv). DMF (0.5 mL) was added dropwise to the suspension and the mixture was warmed to ambient temperature and stirred for 1 h. The mixture was cooled to 0° C. and a solution of diethylamine (25.61 mL, 247.5 mmol, 5.0 equiv) in DCM (250 mL) was slowly added via cannula. The mixture was warmed to ambient temperature and stirred for 30 min. H2O (500 mL) was added followed by 2 M HCl (40 mL) until pH=1-2. The layers were separated and the aqueous layer was further extracted with DCM (3×200 mL). The organic extracts were combined and washed successively with saturated aqueous NaHCO3 (1 x 250 mL) and brine (1 x 250 mL). The organic extracts were dried over Na2SO4 and concentrated under reduced pressure.

[0195] To a solution of the resulting brown oil in DCM (200 mL) cooled to 0 °C was added MCPBA (70-75% equilibrium) (22.781 g, 99.006 mmol, 2.0 equiv). The mixture was allowed to warm to ambient temperature and stirred for 18 h. To the solution was added saturated aqueous NaHCO3 (500 mL) followed by 1 M NaOH (500 mL). The layers were separated and the aqueous layer was further extracted with 10% IPA in DCM (3 x 200 mL). The organic layers were combined, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified via chromatography on silica gel (EtOAc, then 12% MeOH in EtOAc) and concentrated under reduced pressure. The resulting pale yellow oil was dissolved in DCM (50 mL) and hexanes (500 mL) was added slowly to the solution with vigorous stirring. The suspension was cooled to 0° C., filtered, and washed with 100 mL of cold hexane to give 3 (11.041 g, 82%) as a white solid.

[0196] 1 H NMR (400 MHz, CDCl3) δ = 8.32 (t, J = 1.5 Hz, 1H), 8.09 (t, J = 1.3 Hz, 1H), 7.35 (t, J = 1.3 Hz, 1H), 3.54 - 3.46 (m, 2H), 3.29 - 3.21 (m, 2H), 1.24 - 1.12 (m, 6H) ppm. 13 C NMR (100 MHz, CDCl3) δ = 164.3, 141.0, 136.3, 135.9, 126.4, 120.7, 43.5, 39.9, 14.4, 12.8 ppm. LRMS (ES + ) m / z [M + H] + C 10 H 14 BrN2O2 + Calculated for 273.02; Measured for 273.12. IR (Diamond, ATR) ν 3445, 3068, 2973, 2934, 1633 cm -1 . 5-Bromo-6-chloro-N,N-diethylnicotinamide (4) [ka]

[0197] To a -61 °C cooled (CHCl3 / dry ice) solution of 3 (9.900 g, 36.395 mmol, 1.0 equiv) and Et3N (10.15 mL, 72.79 mmol, 2.0 equiv) in DCM (180 mL) was added oxalyl chloride (6.24 mL, 72.8 mmol, 2.0 equiv) slowly dropwise. The mixture was stirred for 30 min, then MeOH (5 mL) was slowly added, then allowed to warm to ambient temperature, followed by the addition of saturated aqueous NaHCO3 (25 mL). The solution was poured into 1 M NaOH (600 mL) and the layers were separated. The aqueous layer was further extracted with DCM (3 x 150 mL). The organic extracts were combined, washed with brine (250 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (25% EtOAc in hexanes) to give 4 (9.442 g, 89%) as a crystalline white solid.

[0198] 1 H NMR (400 MHz, CDCl3) δ = 8.34 (s, 1H), 7.96 (s, 1H), 3.59 - 3.42 (m, 2H), 3.36 - 3.18 (m, 2H), 1.28 - 1.10 (m, 6H) ppm. 13 C NMR (100 MHz, CDCl3) δ = 166.0, 151.5, 145.3, 140.7, 133.0, 120.5, 43.6, 39.9, 14.4, 12.9 ppm. LRMS (ES + ) m / z [M + H] + C 10 H 13 BrClNO + Calculated for 290.99; Found 291.00. IR (Diamond, ATR) ν 2974, 2935, 1627, 1574 cm -1 . Diethyl 2-(3-bromo-5-(diethylcarbamoyl)pyridin-2-yl)malonate (6) [ka]

[0199] To a vigorously stirred mixture of 4 (5.000 g, 17.243 mmol, 1.0 equiv) and NaI (20.676 g, 137.94 mmol, 8.0 equiv) in acetonitrile (40 mL) was slowly added TMSCl (3.28 mL, 25.86 mmol, 1.5 equiv). The mixture was stirred at ambient temperature for 30 min, then heated at reflux for 1 h while ¼ of the reaction volume was removed and collected in a Dean-Stark receiver during this period. The resulting yellow suspension was cooled to ambient temperature, diluted with DCM (150 mL), and added to saturated aqueous NaHCO3 solution (250 mL). With vigorous stirring, saturated aqueous Na2S2O3 solution (100 mL) was added, followed by 1 M NaOH (80 mL). The resulting clear solution was transferred to a separatory funnel and the layers were separated. The aqueous layer was further extracted with DCM (3 x 100 mL). The organic extracts were combined, washed with brine (200 mL), dried over Na2SO4 and concentrated under reduced pressure.

[0200] The resulting pale orange solid was added to a sealable screw-cap flask along with copper(I) iodide (0.861 mmol, 0.164 g, 0.05 equiv), picolinic acid (0.212 g, 1.72 mmol, 0.1 equiv), and Cs2CO3 (16.854 g, 51.729 mmol, 3.0 equiv). 1,4-dioxane (43 mL) and diethyl malonate (5.26 mL, 34.5 mmol, 2.0 equiv) were added and the flask was sealed. The mixture was stirred and heated at 90 °C for 16 h. The mixture was cooled to ambient temperature, filtered through Celite, and the filter cake was washed with EtOAc (200 mL). The filtrate was added to H2O (500 mL), followed by 1 M HCl (10 mL), and the layers were separated. The aqueous layer was further extracted with EtOAc (2×200 mL). The organic extracts were combined, washed with brine (250 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (20% EtOAc in hexanes to 50% EtOAc in hexanes) to give 6 (5.461 g, 76%) as a pale yellow oil.

[0201] 1 H NMR (400 MHz, CDCl3) δ = 8.52 (d, J = 1.8 Hz, 1H), 7.92 (d, J = 1.8 Hz, 1H), 5.22 (s, 1H), 4.34 - 4.23 (m, 4H), 3.62 - 3.44 (m, 2H), 3.38 - 3.19 (m, 2H), 1.32 - 1.10 (m, 12H) ppm. 13 LRMS (ES + ) m / z [M + H] + C 17 H 24 BrN2O5 +Calculated for 415.09; Measured for 415.19. IR (Diamond, ATR) ν 2980, 2937, 1735, 1631 cm -1 . 3-Bromo-5-(diethylcarbamoyl)-2-methylpyridine 1-oxide (8) [ka]

[0202] To a solution of 6 (5.350 g, 12.92 mmol, 1.0 equiv) in MeOH (130 mL) was added 2 M aqueous NaOH (32 mL) and the solution was stirred and heated at 50° C. for 16 h. To the resulting suspension was added 1 M aqueous citric acid (45 mL) to adjust the pH to 4 and the solution was stirred and heated at 60° C. for 24 h. The solution was cooled to ambient temperature and MeOH was removed by concentration under reduced pressure. The solution was added to H2O (250 mL) and extracted with DCM (3×200 mL). The organic layers were combined, washed with brine (250 mL), dried over Na2SO4 and concentrated under reduced pressure.

[0203] To a solution of the resulting residue in DCM (50 mL) cooled to 0 °C was slowly added MCPBA (70-75% equilibrium) (5.946 g, 25.84 mmol, 2.0 equiv). The solution was warmed to ambient temperature and stirred for 22 h. The solution was added to 150 mL of 1 M NaOH and the layers were separated. The aqueous layer was further extracted with 10% isopropyl alcohol in DCM (3 x 100 mL). The organic extracts were combined, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc, then 10% MeOH in EtOAc) to give 8 (3.469 g, 94%) as a white solid.

[0204] 1H NMR (400 MHz, CDCl3) δ = 8.19 (d, J = 0.9 Hz, 1H), 7.4 (d, J = 0.9 Hz, 1H), 3.58 - 3.39 (m, 2H), 3.36 - 3.18 (m, 2H), 2.66 (s, 3H), 1.24 - 1.10 (m, 6H) ppm. 13 C NMR (100 MHz, CDCl3) δ = 164.6, 150.2, 136.2, 133.0, 127.0, 122.1, 43.5, 39.9, 17.4, 14.4, 12.8 ppm. LRMS (ES + ) m / z [M + H] + C 11 H 16 BrN2O2 + Calculated for 287.04; Found 287.12. IR (Diamond, ATR) ν 3455, 2972, 2935, 1632 cm -1 . 5-Bromo-N,N-diethyl-6-(hydroxymethyl)nicotinamide (9) [ka]

[0205] To a 0° C.-cooled solution of 8 (1.301 g, 4.531 mmol, 1.0 equiv) in DCM (22.6 mL) was added trifluoroacetic anhydride (1.57 mL, 11.3 mmol, 2.5 equiv) dropwise. The solution was warmed to ambient temperature and stirred for 4 h, then concentrated under reduced pressure. The residue was redissolved in DCM (22.6 mL) and 2 M aqueous Na2CO3 (45.2 mL) was added. The biphasic solution was stirred vigorously at ambient temperature for 18 h, then poured into H2O (100 mL). The layers were separated and the aqueous layer was further extracted with DCM (3×50 mL). The organic extracts were combined, washed with brine (100 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc) to give 9 (1.119 g, 86%) as a yellow oil.

[0206] 1 H NMR (400 MHz, CDCl3) δ = 8.53 (d, J = 1.7 Hz, 1H), 7.90 (d, J = 1.7 Hz, 1H), 4.77 (d, J = 4.7 Hz, 2H), 4.23 (t, J = 4.7 Hz, 1H), 3.64 - 3.46 (m, 2H), 3.38 - 3.18 (m, 2H), 1.32 - 1.08 (m, 6H) ppm. 13 C NMR (100 MHz, CDCl3) δ = 166.8, 157.6, 144.1, 138.6, 133.2, 118.7, 63.4, 43.6, 39.9, 14.5, 12.9 ppm. LRMS (ES + ) m / z [M + H] + C 11 H 16 Calculated for BrN2O2 287.04; found 287.12. IR (Diamond, ATR) ν 3412, 2972, 2934, 1624, 1588 cm -1 . 5-Bromo-N,N-diethyl-6-(hydroxymethyl)-1-methyl-1,2,3,6-tetrahydropyridine-3-carboxamide (10, major diastereomer) 5-Bromo-N,N-diethyl-6-(hydroxymethyl)-1-methyl-1,2,3,6-tetrahydropyridine-3-carboxamide (11, minor diastereomers) [ka]

[0207] To a solution of 9 (0.980 g, 3.413 mmol, 1.0 equiv) in MeCN (4.25 mL) in a vial was added MeI (1.28 mL, 20.5 mmol, 6.0 equiv). The vial was capped and the solution was heated at 70° C. with stirring for 24 h, then subsequently cooled to ambient temperature. To the mixture was added EtOAc (8.5 mL) with vigorous stirring, followed by hexanes (8.5 mL). The suspension was cooled to 0° C., filtered, and washed with hexanes (2×5 mL). The resulting yellow solid was dried under reduced pressure and used directly in the next step.

[0208] To a 0° C. cooled solution of the resulting methylpyridinium salt (1.285 g, 2.995 mmol, 1.0 equiv) in MeOH (30 mL) was added AcOH (0.51 mL, 8.9 mmol, 3.0 equiv), followed by dropwise addition of NaCNBH3 (0.565 g, 8.98 mmol, 3.0 equiv) in MeOH (6 mL). The solution was warmed to ambient temperature and stirred for 16 h, then concentrated under reduced pressure. The residue was dissolved in EtOAc (100 mL) and added to 1 M NaOH (200 mL). The layers were separated and the aqueous layer was further extracted with EtOAc (3×100 mL). The organic extracts were combined, washed with brine (150 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (3% MeOH in DCM) to give an inseparable mixture of diastereomers 10 (major diastereomer) and 11 (minor diastereomer) (0.726 g, 70%) (5:2 dr) as a pale yellow oil.

[0209] 1 H NMR (400 MHz, CDCl3) δ = 6.21 † (s, 1H), 6.11 * (d, J = 2.8 Hz, 0.4H), 3.94 † (dd, J = 2.0 Hz, 1H), 3.88 - 3.78 (m, 1.4H), 3.70 - 3.64 * (m, 0.4H), 3.59* (dd, J = 8.8, 11.6 Hz, 0.4H), 3.54 - 3.47 † (m, 1H), 3.34 (quint, J = 7.3 Hz, 5.6H), 3.21 * (dd, J = 9.4, 13.6 Hz, 0.4H), 3.14 - 3.08 * (m, 0.4H), 3.02 - 2.92 † (m, 2H), 2.88 - 2.80 † (m, 1H), 2.76 * (dd, J = 5.1, 14 Hz, 0.4H), 2.55 * (s, 1.2H), 2.45 † (s, 3H), 2.24 - 2.14 (m, 4.2H), 1.09 (t, J = 7.1 Hz, 4.2H) ppm. 13 C NMR (100 MHz, CDCl3) δ = 170.22, 170.15, 130.4, 127.6, 123.3, 122.9, 68.6, 67.6, 60.9, 59.6, 53.6, 47.0, 43.5, 42.9, 42.2, 42.1, 41.3, 40.7, 40.4, 36.7, 15.1, 14.9, 13.2, 13.1 ppm. LRMS (ES + ) m / z [M + H] + C 12 H 22 BrN2O2 + Calculated for 305.09; Measured 305.14. IR (Diamond, ATR) ν 3418, 2970, 2934, 2799, 1629 cm -1 .

[0210] † arises exclusively from the major diastereomer 1 H NMR signals. * arise exclusively from the minor diastereomer 1 H NMR signals are meant; unassigned signals arise from both mixtures. N,N-Diethyl-6-(hydroxymethyl)-5-(1H-indol-7-yl)-1-methyl-1,2,3,6-tetrahydropyridine-3-carboxamide (12, the major diastereomer, anti stereochemistry assigned based on the crystal structure of 16) N,N-Diethyl-6-(hydroxymethyl)-5-(1H-indol-7-yl)-1-methyl-1,2,3,6-tetrahydropyridine-3-carboxamide (13, minor diastereomer, syn stereochemistry assigned based on assignment for 12) [ka]

[0211] A mixture of diastereomers 10 and 11 (5:2 dr) (0.698 g, 2.29 mmol, 1.0 equiv), 1,4-dioxane (22.9 mL), indole-7-boronic acid pinacol ester (0.834 g, 3.43 mmol, 1.5 equiv), and 2 M aqueous Na2CO3 (2.29 mL) was added to the vial and the solution was sparged with N2 for 10 min, after which Pd(PPh3)4 (0.132 g, 0.114 mmol, 0.05 equiv) was added. The vial was sealed and the mixture was heated with stirring in a preheated oil bath at 100 °C for 4 h. The mixture was cooled to ambient temperature, added to H2O (400 mL), and extracted with EtOAc (3 x 150 mL). The organic extracts were combined, washed with brine (200 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (2% MeOH in DCM to 10% MeOH in DCM) to give 12 (major diastereomer) (0.398 g, 51%) and 13 (minor diastereomer) (0.148 g, 19%) as an off-white semi-solid.

[0212] Major diastereomer, 12. 1H NMR (400 MHz, CDCl3) δ = 9.46 (s, 1H), 7.56 (d, J = 7.8 Hz, 1H), 7.22 (t, J = 2.8 Hz, 1H), 7.06 (t, J = 7.3 Hz, 1H), 7.00 (dd, J = 0.9, 8.4 Hz, 1H), 6.53 (dd, J = 2.1, 3.2 Hz, 1H), 5.92 (s, 1H), 3.79 (dd, J = 3.0, 11.2 Hz, 1H), 3.74 - 3.66 (m, 1H), 3.50 - 3.28 (m, 5H), 3.26 - 3.08 (m, 3H), 3.07 - 2.96 (m, 1H), 2.52 (s, 2H), 1.23 (t, J = 7.1 Hz, 3H), 1.10 (t, J = 7.1 Hz, 3H) ppm. 13 C NMR (100 MHz, CDCl3) δ = 171.7, 137.3, 135.4, 128.11, 128.05, 124,9, 124.1, 121.4, 119.9, 119.4, 102.4, 66.8, 59.1, 54.0, 43.2, 42.0, 40.3, 39.3, 14.9, 13.1 ppm. LRMS (ES + ) m / z [M + H] + C 20 H 28 N3O2 + Calculated for 342.22; Measured 342.32. IR (Diamond, ATR) ν 3267, 2970, 2932, 1615 cm -1 .

[0213] minor diastereomer, 13; 1H NMR (400 MHz, CDCl3) δ = 9.86 (s, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.29 - 7.24 (m, 1H), 7.07 (t, J = 7.4 Hz, 1H), 6.98 (dd, J = 0.6, 7.6 Hz, 1H), 6.51 (dd, J = 2.1 Hz, 3.2 Hz, 1H), 6.08 - 6.04 (m, 1H0, 3.76 - 3.68 (m, 1H), 3.64 - 3.28 (m, 8H), 3.15 - 3.06 (m 1H), 2.99 (dd, J = 5.7, 13.2 Hz, 1H), 2.66 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H), 1.17 (t, J = 7.1 Hz, 3H) ppm. 13 C NMR (100 MHz, CDCl3) δ = 173.0, 135.7, 135.0, 128.4, 125.6, 125.4, 123.8, 120.0, 119.4, 119.0, 102.1, 64.8, 60.9, 48.6, 42.7, 42.3, 40.6, 34.8, 15.1, 13.3 ppm. LRMS (ES + ) m / z [M + H] + C 20 H 28 N3O2 + Calculated for 342.22; Measured 342.32. IR (Diamond, ATR) ν 3270, 2973, 2934, 1613 cm -1 . N,N-Diethyl-8-methyl-7a,8,9,10-tetrahydro-7H-indolo[7,1-fg][1,7]naphthyridine-10-carboxamide (14, (±)-JRT) [ka]

[0214] To a solution of 12 (0.250 g, 0.732 mmol, 1.0 equiv) in CHCl3 (7.3 mL) cooled to 0 °C was added freshly ground NaOH (0.234 g, 5.86 mmol, 8.0 equiv). A solution of TsCl (0.167 g, 0.878 mmol, 1.2 equiv) in CHCl3 (1.5 mL) was added dropwise over 10 min. The mixture was allowed to warm to ambient temperature and stirred for 1.5 h. The mixture was cooled to 0 °C and DMSO (3.7 mL) was added slowly, then allowed to warm to ambient temperature and stirred for 1 h. The mixture was partitioned between H2O (250 mL) and EtOAc (200 mL) and the layers were separated. The aqueous layer was further extracted with EtOAc (3 x 100 mL). The organic extracts were combined, washed with brine (250 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (8% MeOH in EtOAc to 12% MeOH in EtOAc) to give 14 (0.168 g, 71%) as an off-white semi-solid.

[0215] 1 H NMR (400 MHz, CDCl3) δ = 7.5 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 7.3 Hz, 1H), 7.08 - 7.04 (m, 2H), 6.46 (d, J = 3.0 Hz, 1H), 6.31 (s, 1H), 4.66 (dd, J = 5.4, 11.2 Hz, 1H), 3.90 - 3.82 (m, 1H), 3.80 (t, J = 11.1 Hz, 1H), 3.54 - 3.40 (m, 5H), 3.05 (dd, J = 5.0, 11.2 Hz, 1H), 2.95 (t, J = 10.7 Hz, 1H), 2.59 (s, 3H), 1.26 (t, J = 7.1Hz, 3H), 1.18 (t, J = 7.1Hz, 3H) ppm. 13C NMR (100 MHz, CDCl) δ = 171.2, 133.2, 132.5, 126.3, 126.2, 120.3, 120.0, 118.91, 118.88, 114.9, 101.3, 60.5, 55.8, 48.0, 44.0, 42.1, 40.3, 39.9, 15.0, 13.2 ppm. LRMS (ES + ) m / z [M + H] + C 20 H 26 N3O + Calculated for 324.21; Measured 324.29. IR (Diamond, ATR) ν 2972, 2869, 2798, 1636 cm -1 . Example 2: Preparation of N,N-diethyl-8-methyl-7a,8,9,10-tetrahydro-7H-indolo[7,1-fg][1,7]naphthyridine-10-carboxamide (15, minor diastereomer) [ka]

[0216] To a solution of 13 (0.130 g, 0.381 mmol, 1.0 equiv) in CHCl3 (3.8 mL) cooled to 0 °C was added freshly ground NaOH (0.122 g, 3.05 mmol, 8.0 equiv). A solution of TsCl (0.087 g, 0.46 mmol, 1.2 equiv) in CHCl3 (0.76 mL) was added dropwise over 10 min. The mixture was allowed to warm to ambient temperature and stirred for 1.5 h. The mixture was cooled to 0 °C and DMSO (1.9 mL) was added slowly, then allowed to warm to ambient temperature and stirred for 3 h. The mixture was partitioned between H2O (200 mL) and EtOAc (150 mL) and the layers were separated. The aqueous layer was further extracted with EtOAc (3 x 50 mL). The organic extracts were combined, washed with brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (8% MeOH in EtOAc to 12% MeOH in EtOAc) to give 15 (0.044 g, 36%) as a brown semi-solid.

[0217] 1 H NMR (400 MHz, CDCl3) δ = 7.48 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 7.2 Hz, 1H), 7.08 - 7.02 (m, 2H), 6.45 (d, J = 3.0 Hz, 1H), 6.37 (dd, J = 2.0, 3.6 Hz, 1H), 4.50 (dd, J = 5.5, 11.2 Hz, 1H), 4.02 (t, J = 11.2 Hz, 1H), 3.66 - 3.60 (m, 1H), 3.56 - 3.30 (m, 5H), 3.15 (dd, J = 5.7, 12.2 Hz, 1H), 2.83 (dd, J = 4.8, 12.2 Hz, 1H), 2.62 (s, 3H), 1.27 (t, J = 7.0 Hz, 3H), 1.13 (t, J = 7.0 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl) δ = 171.5, 133.4, 133.4, 126.5, 126.2, 120.4, 120.1, 119.9, 118.9, 114.2, 101.2, 58.6, 52.5, 47.9, 43.6, 42.0, 40.3, 37.4, 15.0, 13.2 ppm. LRMS (ES + ) m / z [M + H] + C 20 H 26 N3O + Calculated for 324.21; Measured for 324.29. IR (Diamond, ATR) ν 2969, 2932, 2871, 2791, 1634 cm -1 . Example 3: Thermodynamic Equilibrium [ka]

[0218] Diastereomers 14 and 15 (1:2 ratio, 1 To a solution of 1H NMR (0.014 g, 0.043 mmol, 1.0 equiv) was added 2 M aqueous NaOH (0.5 mL). The solution was heated at 60° C. for 1 h and then concentrated under reduced pressure. The mixture was partitioned between H2O (20 mL) and DCM (10 mL) and the layers were separated. The aqueous layer was further extracted with DCM (2×10 mL). The organic extracts were combined, washed with brine (20 mL), dried over Na2SO4 and concentrated under reduced pressure. Diastereomers 14 and 15 were obtained as a 5:1 mixture (with 14 as the major diastereomer and 15 as the minor diastereomer) of 14 and 15. 1 1 H NMR analysis) and indicates 14 as the thermodynamically favored product, see Figure 7. Example 4: Fumarate salt [ka]

[0219] To a solution of fumaric acid (0.051 g, 0.438 mmol, 1.05 equiv) in acetone (6 mL) was slowly added 14 (0.135 g, 0.417 mmol, 1.0 equiv) in acetone (2 mL) with stirring at 50 °C. The solution was slowly cooled to room temperature with stirring, and hexane (15 mL) was slowly added. The suspension was cooled to 0 °C for 1 h and then subsequently chilled in a -20 °C freezer overnight. The resulting mixture was filtered, washed with ice-cold 1:1 acetone / hexane (2 mL), and dried in a vacuum oven at 50 °C to give (±)-JRT·Fumarate (1:1 salt, 0.126 g, 69%) as a beige solid. 1 H NMR (400 MHz, MeOD4) δ = 7.45 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 7.3 Hz, 1H), 7.21 (d, J = 3.1 Hz, 1H), 7.03 (t, J = 7.6 Hz, 1H), 6.74 (s, 2H), 6.44 (d, J = 3.04 Hz, 1H), 6.36 (s, 1H), 4.94 - 4.86 (m, 1H), 4.08 - 4.00 (m, 1H), 3.80 (t, J = 11.1 Hz, 1H), 3.72 - 3.65 (m, 1H), 3.56 (q, J = 7.2 Hz, 2H), 3.45 (septet, J = 7.6 Hz, 2H), 3.29 - 3.23 (m, 1H), 2.99 (t, J = 11.1 Hz, 1H), 2.74 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H), 1.18 (t, J = 7.1 Hz, 3H) ppm. 13 C NMR (100 MHz, MeOD4) δ = 173.0, 168.8, 135.4, 134.4, 133.1, 128.0, 127.8, 121.32, 121.26, 119.2, 119.1, 115.8, 102.4, 61.6, 56.4, 47.7, 43.8, 43.6, 42.0, 40.2, 15.1, 13.3 ppm. LRMS (ES +) m / z [M + H] + C 20 H 26 N3O + Calculated for 324.21; Measured 324.35. IR (Diamond, ATR) ν 2971, 2869, 2799, 1630 cm -1 . Example 5: Chiral separation of (+)-JRT and (-)-JRT [ka]

[0220] Racemic (±)-JRT (14) was separated into its enantiomers by preparative chiral HPLC using an Agilent 1260 Infinity II (Chiralpak-IC 250 × 30 mm, 5 μm; eluent: 50:50 mixture of 0.1% diethylamine in n-hexane (v / v) and 50% MeOH in CH2Cl2 (v / v); 35.0 mL / min).

[0221] First eluting peak, (-)-JRT. See Figure 9. Analytical Chiral HPLC t = 7.81 min (Chiralpak-IC 250 × 4.6 mm, 5 μm; eluent: 50:50 mixture of 0.1% DEA and isopropanol in n-hexane, 1.0 mL / min). 250 mg, light brown semi-solid; LC-MS: m / z = 324.1 [M+H] + .

[0222] (-)-JRT·Fumarate. In a sealed tube, fumaric acid (81 mg, 0.69 mmol, 1.0 equiv) in acetone (0.81 mL) was heated to 40 °C and stirred for 1 h. To the resulting clear solution, (-)-JRT (226 mg, 0.69 mmol, 1.0 equiv) dissolved in acetone (1.13 mL) was added, and the mixture was stirred at 40 °C for 2 h. After cooling to room temperature, the volatiles were evaporated to give a residue, which was triturated with diethyl ether followed by n-pentane to give a light brown semi-solid, which was further lyophilized to give 270 mg of (-)-JRT as a 1:1 fumarate salt (light brown solid). NMR data were consistent with those reported for (±)-JRT. Specific rotation [α] D 20 -9.9 (c=0.0011 in ethanol).

[0223] Second eluting peak. See Figure 10. Analytical Chiral HPLC R t = 10.14 min (Chiralpak-IC 250 × 4.6 mm, 5 μm; eluent: 50:50 mixture of 0.1% DEA and isopropanol in n-hexane, 1.0 mL / min). 290 mg, light brown semi-solid; LC-MS: m / z = 324.1 [M+H] + .

[0224] (+)-JRT·Fumarate. In a sealed tube, fumaric acid (95 mg, 0.82 mmol, 1.0 equiv) was added to acetone (0.95 mL) and heated to 40 °C and stirred for 1 h. The resulting clear solution was treated with (+)-JRT (266 mg, 0.82 mmol, 1.0 equiv) dissolved in acetone (1.33 mL) and stirred at 40 °C for 2 h. After cooling to room temperature, the volatiles were evaporated to give a residue which was triturated with diethyl ether followed by n-pentane to give a light brown solid which was further lyophilized to give 250 mg of (+)-JRT as a 1:1 fumarate salt (light brown solid). NMR data were consistent with those reported for (±)-JRT. Specific rotation [α] D 20+8.7 (c=0.0011 in ethanol). Example 6: (7aS,10R)-10-(diethylcarbamoyl)-8,8 dimethyl 7a,8,9,10-tetrahydro-7H-indolo[7,1-fg][1,7]naphthyridine octium iodide (16) [ka]

[0225] A mixture of (+)-JRT·fumarate (0.030 g), saturated aqueous NaHCO3 (30 mL), and DCM (30 mL) was stirred vigorously for 20 min. The layers were separated and the aqueous layer was further extracted with DCM (2×30 mL). The combined organic extracts were washed with brine (1×50 mL), dried over Na2SO4, and concentrated under reduced pressure. The resulting free base was dissolved in DCM (4 mL), then methyl iodide (0.4 mL) was added, and the solution was stirred in a 1-dram vial at ambient temperature for 14 h. Upon reaction completion, the stir bar was removed and the 1-dram vial was placed in a 20 mL scintillation vial containing a solution of hexane (5 mL) and Et2O (5 mL) as antisolvent for vapor diffusion. The 2-chamber system was sealed only by capping the outer 20 mL scintillation vial and allowed to sit in the dark at ambient temperature for 1 month, during which time crystals suitable for X-ray diffraction analysis precipitated. A single crystal was used for X-ray analysis, and the remainder was filtered, washed with ice-cold EtO (1 mL), and dried in vacuum to give 16 (0.019 g, 60%) as a light brown crystalline solid. 1H NMR (400 MHz, CDCl3) δ = 7.55 (d, J = 7.0 Hz, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.32 (d, J = 2.9 Hz, 1H), 7.12 (t, J = 7.7 Hz, 1H), 6.63 (s, 1H), 6.54 (d, J = 3.0 Hz, 1H), 5.18 - 5.10 (m, 1H), 5.06 - 4.99 (m, 1H), 4.34 - 4.26 (m, 1H), 4.21 (t, J = 11.3 Hz, 1H), 4.06 (t, J = 11.4 Hz, 1H), 3.99 - 3.92 (m, 1H), 3.76 - 3.62 (m, 2H), 3.59 (s, 3H), 3.56 - 3.40 (m, 2H), 3.35 (s, 3H), 1.38 (t, J = 3.1 Hz, 3H), 1.20 (t, J = 3.1 Hz, 3H) ppm. LRMS (ES + ) m / z [M] + C 21 H 28 N3O + Calculated for 338.22; Measured 338.45. IR (Diamond, ATR) ν 3456, 2971, 2932, 1633 cm -1 . Example 7: X-ray crystallography

[0226] Approximate orthogonal dimensions: 0.248 x 0.448 x 0.594 mm 3 An orange block bearing the fluorine atom was placed and optically centered by a Bruker Duo APEXII CCD system at -183 °C (90 K). Indexing of the unit cell used a random set of reflections well distributed in reciprocal space, collected from three series of 0.5° wide ω-scans, 10 s / frame, and 30 frames / series. Five ω-scan data frame series were collected using 0.3° wide scans, 15 s / frame, and 606 frames collected per series at variable φ angles (φ = 0°, 72°, 144°, 216°, 288°) [MoK αThe distance from the crystal to the detector was 5.15 cm, which resulted in a 2θ max = 61.40°. [Table 1] [Table 2] [Table 3]

[0227] Structure determination and refinement. All crystallographic calculations were performed on a 1.30 GHz Intel i7-1065G7 with 4 cores, 8 processors and a Surface Pro7 with 16 GB extended memory. The collected data were corrected for Lorentz and polarization effects using Saint and for absorption using the method of Blessing, and merged as implemented with the program Sadabs. The SHELXTL program package was implemented to determine the possible space groups and set up the initial files. System symmetry, extinction rules, and intensity statistics indicated a non-centrosymmetric orthorhombic space group P212121 (No. 19). The structure was determined by direct methods with the molecule positioned using the program XT. The structure was refined using XL. The collected 48297 data were merged to 28854 based on the same factors, and then merged for least-squares refinement to 7321 unique data [R(int)=0.0163]. All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were idealized throughout the final refinement stage. The final structure was calculated with R(F) = 1.89% and wR(F 2 ) = 4.96%, GOF = 1.081 [for those 7222 data with Fo > 4σ(Fo), R(F) = 1.84, wR(F 2The structure was refined to convergence with a .DELTA.(x)=4.93]. The final difference-Fourier map had no features that indicated the structure was correct and complete. An empirical correction for extinction was also attempted and found to be negative and therefore was not applied. The absolute geometric parameters of the structure were determined to be: Flack(x), -0.014(3); Hooft(y), -0.013(2) and Parsons(z), -0.013(3), indicating that the absolute configuration of the structure was accurately determined; these values ​​would approach approximately 1.0 if the structure were inverted. Example 8: Serotonin Assay

[0228] Serotonin 5-HT2A in vitro radioligand binding competition assay. 5-HT2A radioligand binding competition assays were performed using conventional methods at Epics Therapeutics SA (Belgium, FAST-0505B). Briefly, competitive binding is performed in duplicate in wells of a 96-well plate (Master Block, Greiner, 786201) containing binding buffer (optimized for each receptor), membrane extract (amount of protein / well optimized for each receptor), radiotracer [3H]-DOI (final concentration optimized for each receptor), and test compound. Nonspecific binding is determined by co-incubation with a 200-fold excess of cold competitor. Samples are incubated in a final volume of 0.1 ml at the optimal temperature and duration for each receptor and then filtered onto a filter plate. Filters are washed six times with 0.5 ml ice-cold wash buffer (optimized for each receptor) and 50 μl of Microscint 20 (Packard) is added to each well. Plates are incubated for 15 minutes on an orbital shaker, after which counts are performed on a TopCount™ for 1 minute / well.

[0229] Serotonin 5-HT2A in vitro cellular IPOne agonist assay. 5-HT2A IPOne HTRF assays were performed at Epics Therapeutics SA (Belgium, FAST-0505I) using conventional methods. Briefly, CHO-K1 cells expressing human recombinant 5-HT2A receptors grown to mid-log phase in antibiotic-free medium were detached with PBS-EDTA, centrifuged, and resuspended in medium without antibiotic buffer. 20,000 cells were dispensed into 96-well plates and incubated overnight at 37°C, 5% CO2.

[0230] For agonist testing, the medium is removed and 20 μl of assay buffer and 20 μl of test compound or reference agonist are added into each well. Plates are incubated for 60 minutes at 37° C. with 5% CO2.

[0231] After adding lysis buffer containing IP1-d2 and anti-IP1 cryptate detection reagent, the plate is incubated at room temperature for 1 hour and the fluorescence ratio is measured using an HTRF kit according to the manufacturer's specifications.

[0232] Serotonin 5-HT2C in vitro radioligand binding competition assay. 5-HT2C edited (accession no. AAF35842.1) radioligand binding competition assays were performed using conventional methods at Epics Therapeutics SA (Belgium, FAST-0507B). Briefly, competitive binding is performed in duplicate in wells of a 96-well plate (Master Block, Greiner, 786201) containing binding buffer (optimized for each receptor), membrane extract (amount of protein / well optimized for each receptor), radioactive tracer [3H]-DOI (final concentration optimized for each receptor), and test compound. Nonspecific binding is determined by co-incubation with a 200-fold excess of cold competitor. Samples are incubated in a final volume of 0.1 ml at the optimal temperature and duration for each receptor and then filtered onto a filter plate. Filters are washed six times with 0.5 ml ice-cold wash buffer (optimized for each receptor) and 50 μl of Microscint 20 (Packard) is added to each well. Plates are incubated for 15 minutes on an orbital shaker, after which counts are performed on a TopCount™ for 1 minute / well.

[0233] Serotonin 5-HT2C in vitro cellular IPOne agonist assay. 5-HT2C IPOne HTRF assay was performed at Epics Therapeutics SA (Belgium, FAST-0507I) using conventional methods. Briefly, CHO-K1 cells expressing human recombinant 5-HT2C editing receptor (accession number AAF35842.1) grown to mid-log phase in antibiotic-free medium were detached with PBS-EDTA, centrifuged, and resuspended in antibiotic buffer-free medium. 20,000 cells were dispensed into 96-well plates and incubated overnight at 37°C, 5% CO2.

[0234] For agonist testing, the medium is removed and 20 μl of assay buffer and 20 μl of test compound or reference agonist are added into each well. Plates are incubated for 60 minutes at 37° C. with 5% CO2.

[0235] After adding lysis buffer containing IP1-d2 and anti-IP1 cryptate detection reagent, the plate is incubated at room temperature for 1 hour and the fluorescence ratio is measured using an HTRF kit according to the manufacturer's specifications. Example 9: Neurite Assay

[0236] Neurite outgrowth in primary neuronal cell culture assays. Altered patterns of neurite outgrowth are implicated in trauma as well as psychiatric and neurodegenerative disorders. The discovery of novel compounds that can positively affect neuritogenesis is important for developing new treatments for neurological diseases. Measurement of neurite outgrowth in rat cortical neurons using an automated image-based assay is used to determine the neuroplasticity effects of the compounds of the invention. Neurite outgrowth assays were performed at Neurofit SAS (France) as described below.

[0237] Pregnant Wistar rats (Janvier, France) were used for the study. Wistar rats were delivered 6 days before use. Upon arrival at Neurofit's animal facility, Wistar rats were housed individually per cage and maintained in a room with controlled temperature (21–22 °C) and a reversed light / dark cycle (12 h / 12 ​​h, lights on: 17:30–05:30, lights off: 05:30–17:30) with food and water available ad libitum.

[0238] Female Wistar rats on day 17 of gestation were killed by cervical dislocation and fetuses were removed from the uterus. The brains were placed in ice-cold Leibovitz medium (L15, Gibco, Fisher bioblock, France). The cerebral cortex was dissected and the meninges were carefully removed. Cortical neurons were dissociated by trypsinization (trypsin-EDTA, Gibco) in the presence of 0.1 mg / ml DNAse I (Roche, France) for 30 min at 37°C. The reaction was stopped by the addition of Dulbecco's modified Eagle's medium (DMEM, Gibco) containing 10% fetal bovine serum (FBS, Gibco). The suspension was triturated with a 10 ml pipette using a needle syringe 21 G and centrifuged at 350 × g for 10 min at room temperature. Dissociated cell pellets were resuspended in medium consisting of Neurobasal (Gibco) supplemented with 2% B27 supplement (Gibco), 0.5 mM L-glutamine (Gibco) and antibiotic-antimicrobial mixture. Viable cells were counted in a Neubauer cytometer using a trypan blue dye exclusion test (Sigma). Cells were seeded at a density of 10,000 cells per well in poly-L-lysine pre-coated 96-well plates (Costar). Different concentrations of test compounds were added to the cultures. Donepezil (positive control) was tested at 250 nM.

[0239] After plating for 72 h (3 days), cultures were fixed with paraformaldehyde (4%, Sigma) in PBS for 30 min at 4 °C. Next, cells were successively permeabilized with 0.1% Triton X100 for 30 min, saturated with PBS containing 3% BSA, and incubated with anti-βIII tubulin antibody (Sigma) at 1 / 10 000 in PBS containing 0.5% BSA for 1 h. Cells were washed three times with PBS containing 0.5% BSA and incubated with goat anti-mouse antibody conjugated with AF488 (Invitrogen A11001) diluted at 1 / 1000 in PBS containing 0.5% BSA for 1 h. Finally, nuclei were stained with DAPI 1 mg / ml at 1 / 1000 in PBS containing 0.5% BSA. After washing with PBS, plates were photographed and neurite networks were examined and analyzed using High-Content Screening (CellInsight, Thermo Scientific). The mean neurite number per neuron and the mean total neurite length per neuron were the main parameters analyzed. Data were analyzed using analysis of variance (ANOVA). Fisher's Protected Least Significant Difference test was used for multiple comparisons. A p value of ≦0.05 was considered significant. The software used was StatView 5.0 from SAS Institute.

[0240] In some embodiments, the compounds of the present invention increase the pattern of neurite outgrowth. In some embodiments, the compounds of the present invention increase the average neurite length compared to a control. In some embodiments, the compounds of the present invention increase the branch points of neurites compared to a control. In some embodiments, the compounds of the present invention significantly increase the number of new neurites and / or the average neurite length and / or the total length of dendritic branches compared to a control.

[0241] Although the foregoing invention has been described in some detail by way of illustrations and examples for purposes of clarity of understanding, those skilled in the art will recognize that certain changes and modifications may be practiced within the scope of the appended claims.Furthermore, each reference provided herein is incorporated by reference in its entirety to the same extent as if each reference was individually incorporated by reference.In the event of any conflict between this application and the references provided herein, this application shall control.

Claims

1. The following formula (K): 【Chemistry 1】 {During the ceremony, Each R 1a , R 1b , R 1c , and R 1d are independent of each other, H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, halogen, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, -NO 2 or -CN; Alternatively, two R on adjacent ring atoms 1a The groups are combined to form C 4-8 forming a cycloalkyl or a 4-8 membered heterocycloalkyl having 1-2 heteroatoms each independently being N, O, or S; R 2a and R 2b are independently H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, C 1-6 Haloalkyl, or C 1-6 is haloalkoxy; Or, R 2a and R 2b are combined to form a 4-8 membered heterocycloalkyl having 1-2 heteroatoms, each independently N, O, or S; R 3 , H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkoxyalkyl, C 1-6 Haloalkyl, or C 1-6 haloalkoxy; R 3a is absent or C 1-6 Is it alkyl; Or, R 3 and R 3a are combined to form a 3- to 8-membered heterocycloalkyl having 1-2 heteroatoms, each independently N, O, or S; the subscripts m and p are each independently 0 to 2; and the subscripts n and r each independently represent 0 to 3}, or a pharma- ceutical acceptable salt thereof.

2. The following formula (I): 【Chemistry 2】 2. The compound of claim 1 having the structure:

3. Formula (Ia), (Ib), (Ic), or (Id): 【Chemistry 3】 2. The compound of claim 1 having the structure:

4. R 1a But, H, C 1-6 Alkyl, C 1-6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is aryl, aryloxy, arylsulfonyl, arylsulfate, arylsulfonyl ...

5. R 1a is H; or a pharma- ceutically acceptable salt thereof.

6. R 2a and R 2b However, independently, H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxyalkyl, or C 1-6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, which is haloalkyl.

7. R 2a and R 2b However, each independently, C 1-6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is 1 or 2;

8. R 2a and R 2b or a pharma- ceutical acceptable salt thereof, according to claim 1, wherein each is independently ethyl.

9. R 3 But H or C 1-6 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is 1 or 2;

10. R 3 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein is methyl.

11. The structure: 【Chemistry 4】 2. The compound of claim 1, having the formula:

12. The structure: 【Chemistry 5】 2. The compound of claim 1 having the formula:

13. The structure: 【Chemistry 6】 2. The compound of claim 1, having the formula:

14. The structure: 【Chemistry 7】 2. The compound of claim 1, having the formula:

15. The structure: 【Chemistry 8】 2. The compound of claim 1 having the formula:

16. The structure: 【Chemistry 9】 2. The compound of claim 1 having the formula:

17. The following structure is characterized by unit cell dimensions of a = 7.0716(6) Å, α = 90°, b = 14.4326(12) Å, β = 90°, c = 23.0876(19) Å, and γ = 90°: 【Chemistry 10】 A crystalline compound of (7aS,10R)-10-(diethylcarbamoyl)-8,8-dimethyl-7a,8,9,10-tetrahydro-7H-indolo[7,1-fg][1,7]naphthyridin-8-ium iodide having the formula:

18. 18. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof.

19. A pharmaceutical composition for treating a disease comprising a therapeutically effective amount of a compound according to any one of claims 1 to 17 or a pharma- ceutical acceptable salt thereof.

20. 20. The pharmaceutical composition of claim 19, wherein the disease is a neuropsychiatric disease.

21. 21. The pharmaceutical composition of claim 20, wherein the neuropsychiatric disease is schizophrenia.

22. 21. The pharmaceutical composition of claim 20, wherein the neuropsychiatric disease is bipolar disorder.

23. 20. The pharmaceutical composition of claim 19, wherein the disease is depression.

24. 20. The pharmaceutical composition of claim 19, wherein the disease is a neurodegenerative disease.

25. 20. The pharmaceutical composition of claim 19, wherein the disease is Alzheimer's disease.

26. 20. The pharmaceutical composition of claim 19, wherein the disease is Parkinson's disease.

27. 20. The pharmaceutical composition of claim 19, wherein the disease is a headache disorder.

28. The pharmaceutical composition of claim 190, wherein the disease is migraine.

29. 20. The pharmaceutical composition of claim 19, wherein the disease is cluster headache.

30. 20. The pharmaceutical composition of claim 19, wherein the disease is addiction.

31. 20. The pharmaceutical composition of claim 19, wherein the disease is a substance use disorder.

32. 20. The pharmaceutical composition of claim 19, wherein the disease is an alcohol use disorder.

33. 20. A pharmaceutical composition for enhancing neuroplasticity, comprising a compound according to any one of claims 1 to 17 or a pharma- ceutical acceptable salt thereof in an amount sufficient to enhance neuroplasticity in a neuronal cell, wherein the compound causes the maximum number of dendritic intersections to be increased by more than 1.0-fold according to Sholl analysis.

34. 20. A pharmaceutical composition for enhancing neuroplasticity and increasing dendritic spine density, comprising a compound according to any one of claims 1 to 17 or a pharma- ceutical acceptable salt thereof in an amount sufficient to enhance neuroplasticity and increase dendritic spine density in a neuronal cell.

Images